A cross-disorder analysis of CNVs finds novel loci and dose-dependent relationships of genes to psychiatric traits

Omar Shanta[1,2], Marieke Klein[2,3,4], Molly Sacks[1,2], Jeffrey R. MacDonald[5,6], Adam Maihofer[2,7,8], Mohammad Ahangari[2], Worrawat Engchuan[5,6], Bhooma Thiruvahindrapuram[5,6], James Guevara[2], Oanh Hong[2], Guillaume Huguet[9], Ida Sønderby[10,11,12], Maria Kalyuzhny[2], Mark J. Adams[13], Rolf Adolfsson[14], Ingrid Agartz[15,16,17], Allison E. Aiello[18], Martin Alda[19,20], Judith Allardyce[21], Ananda B. Amstadter[22], Till F.M. Andlauer[23], Ole A. Andreassen[10,12,24], María S. Artigas[25,26,27,28], S. Bryn Austin[29,30,31], Muhammad Ayub[32], Dewleen G. Baker[2], Nick Bass[33], Bernhard T. Baune[34,35,36], Maximilian Bayas[37], Klaus Berger[38], Joanna M. Biernacka[39,40], Tim Bigdeli[41], Jonathan I. Bisson[42], Douglas Blackwood[21], Marco Boks[43], David Braff[2], Elvira Bramon[33], Gerome Breen[44], Tanja Brueckl[45], Richard A. Bryant[46], Cynthia M. Bulik[47,48,49], Joseph Buxbaum[50], Murray J. Cairns[51,52], Jose M. Caldas-de-Almeida[53], Megan Campbell[54], Dominique Campion[55], Vaughan J. Carr[56,57], Enrique Castelao[58], Boris Chaumette[59], Sven Cichon[60], David Cohen[61,62], Aiden Corvin[63], Nicholas Craddock[64], Jennifer Crosbie[65,66], Darrina Czamara[67], Udo Dannlowski[68,69], Franziska Degenhardt[60], Douglas L. Delahanty[70], Astrid Dempfle[71], Guillaume Desachy[72,73], Arianna Di Florio[74], Faith B. Dickerson[75], Srdjan Djurovic[12,76,77], Katharina Domschke[78], Lisa Douglas[79], Ole K. Drange[76,80], Laramie E. Duncan[81,82], Howard J. Edenberg[83,84], Tonu Esko[85], Steve Faraone[86], Norah C. Feeny[87], Andreas J. Forstner[88,89,90,91,92], Barbara Franke[93,94], Mark Frye[95], Dong-jing Fu[96], Janice M. Fullerton[97,98], Anna Gareeva[100,101,102,99], Linda Garvert[103], Justine M. Gatt[46], Pablo Gejman[104], Daniel H. Geschwind[105], Ina Giegling[106], Stephen J. Glatt[107], Joe Glessner[108,109,110], Fernando S. Goes[111], Katherine Gordon-Smith[112], Hans Grabe[103], Melissa J. Green[113], Michael F. Green[114,115], Tiffany Greenwood[2], Maria Grigoroiu-Serbanescu[116], Raquel E. Gur[117], Ruben C. Gur[117], Jose Guzman-Parra[118], Jan Haavik[119], Tim Hahn[69], Hakon Hakonarson[108,109,110], Joachim Hallmayer[120,121], Marian L. Hamshere[122], Annette M. Hartmann[123], Arsalan Hassan[124], Caroline Hayward[125], Johannes Hebebrand[126,127], Sian M.J. Hemmings[128,129], Stefan Herms[60], Marisol Herrera-Rivero[130,35,68], Anke Hinney[126,131,132], Georg Homuth[133], Andrés Ingason[134], Lucas T. Ito[135,136,137,138,139], Nakao Iwata[140], Ian Jones[141], Lisa A. Jones[112], Lina Jonsson[142], Erik G. Jönsson[15,16], René S. Kahn[137], Robert Karlsson[143], Milissa L. Kaufman[144,145], John R. Kelsoe[2], James L. Kennedy[146,66], Anthony King[147], Tilo Kircher[148,149], George Kirov[150], Per Knappskog[151,152], James A. Knowles[153,154], Nene Kobayashi[155], Karestan C. Koenen[156], Bettina Konte[123], Mayuresh Korgaonkar[157], Kaarina Kowalec[143], Marie-Odile Krebs[59], Mikael Landén[142,143], Claudine Laurent-Levinson[158,62], Lauren A. Lebois[145,159], Doug Levinson[81], Cathryn Lewis[160,44], Qingqin Li[96], Israel Liberzon[161], Greg Light[2], Sandra K. Loo[162], Yi Lu[143,163], Susanne Lucae[45], Charles Marmar[164], Nicholas G. Martin[165], Fermin Mayoral[118], Andrew M. McIntosh[166], Katie A. McLaughlin[167], Samuel A. McLean[168,169], Andrew McQuillin[33], Sarah E. Medland[170,171,172], Andreas Meyer-Lindenberg[173], Vihra Milanova[174], Philip B. Mitchell[113], Esther Molina[175,176], Bryan Mowry[177,178], Bertram Muller-Myhsok[179,180], Niamh Mullins[136,137,138], Robin Murray[181], Markus M. Nöthen[60], John I. Nurnberger Jr[182,183], Kevin S. O'Connell[24,76], Roel A. Ophoff[184], Holly K. Orcutt[185], Michael J. Owen[186], Aarno Palotie[187,188,189], Carlos Pato[190], Michele Pato[190], Joanna Pawlak[191], Triinu Peters[126,131,132], Tracey L. Petryshen[192], Giorgio Pistis[58], James B. Potash[111], John Powell[193], Martin Preisig[58], Digby Quested[194], Josep A. Ramos-Quiroga[25,26,27,28], Andreas Reif[195], Kerry J. Ressler[145,196,197], Marta Ribasés[25,26,27,28], Marcella Rietschel[198], Victoria B. Risbrough[2,7], Margarita Rivera[175,199], Alex O. Rothbaum[196,200], Barbara O. Rothbaum[196], Dan Rujescu[106], Takeo Saito[140], Alan R. Sanders[201], Russell J. Schachar[65,66], Peter R. Schofield[113], Eva C. Schulte[202,203,204,205,60], Thomas G. Schulze[204], Laura J. Scott[206], Soraya Seedat[207,208], Christina Sheerin[22], Jianxin Shi[209], Pamela Sklar[210], Susan Smalley[162,211], Olav B. Smeland[24,76], Jordan W. Smoller[212,213], Edmund Sonuga-Barke[214], David St. Clair[215], Nils Eiel Steen[216,24,76], Dan Stein[217], Frederike Stein[148,149], Murray B. Stein[2,218,219], Fabian Streit[173,198,220,221], Neal Swerdlow[2], Florence Thibaut[222,223], Johan H. Thygesen[224,33], Ilgiz Timerbulatov[102,225,226], Claudio Toma[227,228], Edward Trapido[229], Micheline Tremblay[230], Ming T. Tsuang[2], Monica Uddin[231], Marquis P. Vawter[232], John B. Vincent[146,66], Henry Völzke[233], James T. Walters[186], Cynthia S. Weickert[113,97], Lauren

A. Weiss[73], Myrna M. Weissman[234,235], Thomas Werge[236], Stephanie H. Witt[198,220], Miguel Xavier[237], Robert Yolken[238], Ross M. Young[239,240], Tetyana Zayats[241,242,243], Lori A. Zoellner[244], AGP Consortium, PEIC Psychosis Endophenotypes International Consortium, ADHD Working Group of the Psychiatric Genomics Consortium, Autism Working Group of the Psychiatric Genomics Consortium, Bipolar Disorder Working Group of the Psychiatric Genomics Consortium, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, PTSD Working Group of the Psychiatric Genomics Consortium, Schizophrenia Working Group of the Psychiatric Genomics Consortium, CNV Working Group of the Psychiatric Genomics Consortium, Kimberley Kendall[64], Brien Riley[245], Naomi R. Wray[246,247], Michael C. O'Donovan[64], Patrick F. Sullivan[143,248], Sandra Sanchez-Roige[2,249,250], Caroline M. Nievergelt[2,251], Sébastien Jacquemont[252,253], Stephen W. Scherer[254,255,5,6], Jonathan Sebat[2,249,256,257]∗

[1]Bioinformatics and Systems Biology Graduate Program, University of California San Diego, La Jolla, CA, USA, [2]Department of Psychiatry, University of California San Diego, La Jolla, CA, USA, [3]Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands, [4]Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands, [5]Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada, [6]The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ON, Canada, [7]Veterans Affairs San Diego Healthcare System, Center of Excellence for Stress and Mental Health, San Diego, CA, USA, [8]Veterans Affairs San Diego Healthcare System, Research Service, San Diego, CA, USA, [9]CHU Sainte-Justine Azrieli Research Center, Université de Montréal, Montreal, QC, Canada, [10]Centre for Precision Psychiatry, University of Oslo, Oslo, Norway, [11]Department of Medical Genetics, Oslo University Hospital, Oslo, Norway, [12]KG Jebsen Centre for Neurodevelopmental disorders, University of Oslo, Oslo, Norway, [13]Centre for Clinical Brain Sciences, University of Edinburgh , Edinburgh, UK, [14]Department of Clinical Science, Umeå University, Umeå, Sweden, [15]Institute of Clinical Medicine, University of Oslo, Oslo, Norway, [16]Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Stockholm Region, Stockholm, Sweden, [17]Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway, [18]Department of Epidemiology, Columbia University, Robert N Butler Columbia Aging Center, New York, NY, US, [19]National Institute of Mental Health, Klecany, Czech Republic, [20]Department of Psychiatry, Dalhousie University, Halifax, NS, Canada, [21]Division of Psychiatry, University of Edinburgh, Edinburgh, UK, [22]Department of Psychiatry, Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA, [23]Department of Neurology, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany, [24]Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway, [25]Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain, [26]Department of Mental Health, Hospital Universitari Vall d'Hebron, Barcelona, Spain, [27]Biomedical Network Research Centre on Mental Health (CIBERSAM), Madrid, Spain, [28]Department of Genetics, Microbiology, and Statistics, Faculty of Biology, Universitat de Barcelona (UB), Barcelona, Spain, [29]Boston Children's Hospital, Division of Adolescent and Young Adult Medicine, Boston, MA, USA, [30]Department of Pediatrics, Harvard Medical School, Boston, MA, USA, [31]Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, USA, [32]University College London, London, UK, [33]Division of Psychiatry, University College London, London, UK, [34]The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia, [35]Department of Psychiatry, University of Münster, Münster, Germany, [36]Department of Psychiatry, University of

Melbourne, Melbourne, Australia, [37]Department of Psychiatry, Psychosomatic Medicine and Psychotherapy; University Hospital Frankfurt - Goethe University, Frankfurt, Germany, [38]Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany, [39]Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA, [40]Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA, [41]Department of Psychiatry and Behavioral Sciences, Institute for Genomics in Health, State University of New York Downstate Health Sciences University, Brooklyn, NY, USA, [42]Cardiff University, National Centre for Mental Health, MRC Centre for Psychiatric Genetics and Genomics, Cardiff, UK, [43]University Medical Center, Division of Neurosciences, Department of Psychiatry, Heidelberglaan, Utrecht, the Netherlands, [44]Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK, [45]Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany, [46]School of Psychology, Faculty of Science, University of New South Wales, Sydney, New South Wales, Australia, [47]Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden, [48]Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, [49]Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, [50]Seaver Autism Center, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA, [51]School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, Australia, [52]Precision Medicine Research Program, Hunter Medical Research Institute, Newcastle, New South Wales, Australia, [53]Chronic Diseases Research Centre (CEDOC), Lisbon Institute of Global Mental Health, Lisbon, Portugal, [54]Department of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town, South Africa, [55]INSERM EPI 9906, Faculté de Médecine et de Pharmacie, Institut Fédératif de Recherches Multidisciplinaires sur les peptides, Rouen, France, [56]Department of Psychiatry, Monash University, Melbourne, Australia, [57]School of Psychiatry, University of New South Wales, Sydney, New South Wales, Australia, [58]Psychiatric Epidemiology and Psychopathology Research Center, Department of Psychiatry, Lausanne University Hospital and University of Lausanne, Prilly, Switzerland, [59]Université Paris Cité, Institute of Psychiatry and Neuroscience of Paris (INSERM U1266), GHU Paris Psychiatrie et Neurosciences, Paris, France, [60]Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany, [61]CNRS UMR 7222, Institute for Intelligent Systems and Robotics, Sorbonne University, Paris, France, [62]Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris-Sorbonne University, Paris, France, [63]Department of Psychiatry, Trinity College Dublin, Dublin, Ireland, [64]Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK, [65]Neurosciences & Mental Health, The Hospital for Sick Children, Toronto, ON, Canada, [66]Department of Psychiatry, University of Toronto, Toronto, ON, Canada, [67]Department Genes and Environment, Max-Planck-Institute of Psychiatry, Munich, Germany, [68]Joint Institute for Individualisation in a Changing Environment (JICE), University of Münster and Bielefeld University, Münster, Germany, [69]Institute for Translational Psychiatry, University of Münster, Münster, Germany, [70]Department of Psychological Sciences, Kent State University, Kent, OH, USA, [71]Institute of Medical Informatics and Statistics, UKSH University Hospital of Schleswig-Holstein Kiel Campus, Arnold-Heller-Strasse, Kiel, Germany, [72]Data Science & Biometrics, Research & Development, Pierre Fabre Group, Toulouse, France, [73]Institute for Human Genetics, Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences,

University of California San Francisco, San Francisco, CA, USA, [74]School of Medicine, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK, [75]Sheppard Pratt Health System, Baltimore, MD, USA, [76]Centre for Precision Psychiatry, Oslo University Hospital & University of Oslo, Oslo, Norway, [77]Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway, [78]Department of Psychiatry and Psychotherapy, University of Freiburg, Freiburg, Germany, [79]Cheshire and Wirral Partnership NHS Trust, Ellesmere Port, Cheshire, UK, [80]Department of Psychiatry, Sørlandet hospital, Arendal/Kristiansand, Norway, [81]Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA, [82]Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA, [83]Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA, [84]Department of Biochemistry & Molecular Biology, Indiana University, Indianapolis, IN, USA, [85]Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia, [86]Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, New York, NY, USA, [87]Department of Psychological Sciences, Case Western Reserve University, Cleveland, OH, USA, [88]Department of Psychiatry (UPK), University of Basel, Basel, Switzerland, [89]Institute of Human Genetics, University of Bonn School of Medicine & University Hospital Bonn, Bonn, Germany, [90]Centre for Human Genetics, University of Marburg, Marburg, Germany, [91]Department of Biomedicine, University of Basel, Basel, Switzerland, [92]Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland, [93]Department of Human Genetics, Donders Institute of Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands, [94]Department of Medical Neuroscience, Donders Institute of Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands, [95]Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, US, [96]Janssen Research and Development, LLC, [97]Neuroscience Research Australia, Randwick, New South Wales, Australia, [98]School of Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia, [99]FSBSI Institute of Biochemistry and Genetics of the Ufa Federal Research Center of the Russian Academy of Sciences, Russia, [100]FSBEI HE Kemerovo State University, Russia, [101]FSBEI HE Bashkir State Medical University of Health Ministry of Russia, Russia, [102]FSBEI APGE Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia, Russia, [103]Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany, [104]Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, IL, USA, [105]School of Medicine, University of California Los Angeles, Los Angeles, CA, USA, [106]Department of Psychiatry and Psychotherapy, Comprehensive Center for Clinical Neurosciences and Mental Health (C3NMH), Medical University of Vienna, Austria, [107]Director, Psychiatric Genetic Epidemiology & Neurobiology Laboratory (PsychGENe Lab), SUNY Upstate Medical University, [108]Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, USA, [109]Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, [110]Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, USA, [111]Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA, [112]Psychological Medicine, University of Worcester, Worcester, UK, [113]Discipline of Psychiatry and Mental Health, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia, [114]Center on Enhancement of Community Integration for Homeless Veterans, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA, [115]Semel Institute for Neuroscience and Human

Behavior, University of California Los Angeles, Los Angeles, CA, USA, [116]Psychiatric Genetics Research Unit, Alexandru Obregia Clinical Psychiatric Hospital, Bucharest, Romania, [117]Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA, [118]Unidad de Gestión Clínica de Salud Mental del Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina - IBIMA Plataforma Bionand, Málaga, Spain, [119]JanK.G. Jebsen Centre for Neuropsychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway, [120]Department of Psychiatry and Behavioral Sciences (JKF, PL, BJ, MWM, JH, JY), Stanford University School of Medicine, Stanford, CA, USA, [121]VISN 21 Mental Illness Research, Education, and Clinical Center (JKF, PL, MWM, JH, JY), Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA, [122]Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK, [123]Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria, [124]University of Peshawar, Peshawar, Pakistan, [125]MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, Edinburgh, UK, [126]Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, University of Duisburg-Essen, Essen, Germany, [127]Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics, University Hospital Essen (AöR), University of Duisburg-Essen, Essen, Germany, [128]SAMRC Genomics of Brain Disorders Research Unit, Stellenbosch University, Cape Town, Western Cape, ZA, [129]Faculty of Medicine and Health Sciences, Department of Psychiatry, Stellenbosch University, Cape Town, Western Cape, ZA, [130]Department of Genetic Epidemiology, Institute of Human Genetics, University of Münster, Münster, Germany, [131]Institute of Sex and Gender-Sensitive Medicine, University Hospital Essen, University of Duisburg-Essen, Virchowstr, Essen, Germany, [132]Section of Molecular Genetics of Mental Disorders, LVR-University Clinic Essen, Essen, Germany, [133]Interfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany, [134]Institute of Biological Psychiatry, Mental Health Services, Copenhagen University Hospital, Roskilde, Denmark, [135]Department of Biochemistry, Universidade Federal de São Paulo, São Paulo, Brazil, [136]Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA, [137]Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA, [138]Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA, [139]Laboratory of Integrative Neuroscience, Universidade Federal de São Paulo, São Paulo, Brazil, [140]Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan, [141]Cardiff University, National Centre for Mental Health, Cardiff University Centre for Psychiatric Genetics and Genomics, Cardiff, UK, [142]Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden, [143]Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, [144]McLean Hospital, Belmont, MA, USA, [145]Department of Psychiatry, Harvard Medical School, Boston, MA, USA, [146]Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada, [147]The Ohio State University, College of Medicine, Institute for Behavioral Medicine Research, Columbus, OH, USA, [148]Department of Psychiatry and Psychotherapy, University of Marburg, Marburg, Germany, [149]Center for Mind, Brain and Behavior, University of Marburg, Marburg, Germany, [150]Department of Psychological Medicine and Neurology, MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK, [151]Department of Clinical Science, University of Bergen, Bergen, Norway, [152]Department of

Medical Genetics, Haukeland University Hospital, Bergen, Norway, [153]Human Genetics Institute of New Jersey (HGINJ), Rutgers University, Piscataway, NJ, USA, [154]Department of Genetics, Rutgers University, Piscataway, NJ, USA, [155]Goethe University Frankfurt, University Hospital, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Frankfurt, Germany, [156]Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA., [157]Brain Dynamics Centre, Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales, Australia, [158]Childhood Genetic Disease Laboratory, INSERM UMR S933, Trousseau University Hospital, Paris, France, [159]McLean Hospital, Center of Excellence in Depression and Anxiety Disorders, Belmont, MA, USA, [160]Department of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London, London, UK, [161]Department of Psychiatry and Behavioral Sciences, Texas A&M University College of Medicine, Bryan, TX, USA, [162]Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, USA, [163]College of Pharmacy, University of Manitoba, Winnipeg, MB, Canada, [164]New York University, Grossman School of Medicine, New York City, NY, USA, [165]Brain and Mental Health Program, QIMR Berghofer Institute of Medical Research, Brisbane, Australia, [166]Division of Psychiatry, Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK, [167]Department of Psychology, Harvard University, Boston, MA, USA, [168]Department of Emergency Medicine, UNC Institute for Trauma Recovery, Chapel Hill, NC, USA, [169]Department of Anesthesiology, UNC Institute for Trauma Recovery, Chapel Hill, NC, USA, [170]School of Psychology, The University of Queensland, Brisbane, Queensland, Australia, [171]Mental Health and Neuroscience, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia, [172]School of Psychology and Counselling, Queensland University of Technology, Brisbane, Queensland, Australia, [173]Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, [174]Department of Psychiatry, Faculty of Medicine, Medical University of Sofia, University Hospital Alexandrovska, Bulgaria, [175]Institute of Neurosciences ´Federico Olóriz´, Biomedical Research Centre (CIBM), University of Granada, and Instituto de Investigación Biosanitaria, Ibs Granada, Granada, Spain., [176]Department of Nursing, Faculty of Health Sciences, University of Granada, Granada, Spain., [177]Department of Psychiatry, University of Queensland, Brisbane, Australia, [178]Queensland Centre for Schizophrenia Research, Wolston Park Hospital, Wacol, Queensland, Australia, [179]Max Planck Institute of Psychiatry, Munich, Germany, [180]HMNC Holding GmbH, Munich, Germany, [181]Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience,King's College London, UK, [182]Stark Neurosciences Research Institute, [183]Departments of Psychiatry & Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA, [184]Department of Psychiatry and Biobehavioral Science and Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA, [185]Department of Psychology, Northern Illinois University, DeKalb, IL, USA, [186]Centre for Neuropsychiatric Genetics and Genomics, Division of Psychiatry and Clinical Neurosciences, Cardiff University, Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ, [187]The Stanley Center for Psychiatric Research and Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA, [188]Analytic and Translational Genetics Unit, Department of Medicine, Department of Neurology, and Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA, [189]Institute for Molecular Medicine Finland and the Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland,

[190]Department of Psychiatry, Rutgers University, Piscataway, NJ, USA, [191]Department of Psychiatric Genetics, Poznan University of Medical Sciences, Poznan, Poland, [192]Psychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry and Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, [193]King's College London, London, UK, [194]Oxford NHS Foundation Trust, Oxford, UK, [195]Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt - Goethe University, Frankfurt am Main, Germany, [196]Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, USA, [197]Division of Depression and Anxiety, McLean Hospital, Belmont, MA, US, [198]Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, [199]Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy, University of Granada, Granada, Spain, [200]Department of Research and Outcomes, Skyland Trail, Atlanta, GA, USA, [201]Department of Psychiatry and Behavioral Neuroscience, University of Chicago, [202]German Center for Mental Health (DZPG), Munich, Germany, [203]Department of Psychiatry, University Hospital, Faculty of Medicine, University of Bonn, Bonn, Germany, [204]Institute of Psychiatric Phenomics and Genomics (IPPG), LMU University Hospital, LMU Munich, Munich, Germany, [205]Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany, [206]Department of Biostatistics and Center for Statistical Genetics, School of Public Health, University of Michigan, Ann Arbor, MI, USA, [207]SAMRC Unit on the Genomics of Brain Disorders, Faculty of Medicine and Health Sciences, Department of Psychiatry, Stellenbosch University, Cape Town, Western Cape, ZA, [208]SAMRC Extramural Genomics of Brain Disorders Research Unit, Stellenbosch University, Cape Town, Western Cape, ZA, [209]Division of Cancer Epidemiology and Genetics National Cancer Institute, Rockville, MD, USA, [210]Icahn School of Medicine at Mount Sinai, New York, NY, USA, [211]Net.bio Inc, Los Angeles, CA, USA, [212]Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA, [213]Center for Precision Psychiatry, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA, [214]Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK, [215]Department of Mental Health, University of Aberdeen, Royal Cornhill Hospital, Aberdeen, UK., [216]Division of Mental Health and Substance abuse, Diakonhjemmet Hospital, Oslo, Norway, [217]SAMRC Unit on Risk and Resilience in Mental Disorders, Dept of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town, South Africa, [218]School of Public Health, University of California San Diego, La Jolla, CA, USA, [219]Veterans Affairs San Diego Healthcare System, Psychiatry Service, San Diego, CA, USA, [220]German Center for Mental Health (DZPG), Partner Site Mannheim - Heidelberg - Ulm, Germany, [221]Hector Institute for Artificial Intelligence in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, [222]INSERM Unit 894, Institute of Psychiatry And Neuroscience of Paris, Paris, France, [223]Cochin University Hospital, Paris Cité University, Paris, France, [224]Institute for Health Informatics, University College London, London, UK, [225]SBI MD Central Clinical Psychiatric Hospital F. Usoltseva, [226]FSBEI HE "Russian University of Medicine" of the Ministry of Health of Russia, Russia, [227]School of Biomedical Sciences, Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia, [228]Neuroscience Research Australia, Sydney, New South Wales, Australia, [229]School of Public Health and Department of Epidemiology, Louisiana State University Health Sciences Center, New Orleans, LA, US, [230]Cheshire and Wirral Partnership NHS Foundation Trust, Winsford, Cheshire, UK,

[231]Genomics Program, University of South Florida College of Public Health, Tampa, FL, USA, [232]Department of Psychiatry & Human Behavior, University of California, Irvine, CA, USA, [233]Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany, [234]New York State Psychiatric Institute, New York, NY, USA, [235]Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA, [236]Institute of Biological Psychiatry, Mental Health Services, Copenhagen University Hospital, Copenhagen, Denmark, [237]Universidade Nova de Lisboa, Nova Medical School, Lisboa, Portugal, [238]Stanley Division of Developmental Neurovirology, Johns Hopkins School of Medicine, Baltimore, MD, USA, [239]University of the Sunshine Coast, The Chancellory, Sippy Downs, Queensland, Australia, [240]Queensland University of Technology, School of Clinical Sciences, Kelvin Grove, Queensland, Australia, [241]Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA, [242]Stanley Center for Psychiatric Research, Broad Institute of MIT, and Harvard, Cambridge, MA, USA, [243]Department of Biomedicine, University of Bergen, Bergen, Norway, [244]Department of Psychology, University of Washington, Seattle, WA, USA, [245]Department of Psychiatry, Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA, [246]Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK, [247]Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland, Australia, [248]Departments of Genetics and Psychiatry, University of North Carolina, Chapel Hill, NC, USA, [249]Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA, [250]Department of Medicine, Division of Genetic Medicine, Vanderbilt University, Nashville, TN, USA, [251]Research/Psychiatry, Veterans Affairs San Diego Healthcare System, San Diego, CA, USA, [252]Centre Hospitalier Universitaire Sainte-Justine Research Center, Montreal, QC, Canada, [253]Department of Pediatrics, Université de Montréal, Montreal, QC, Canada, [254]Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada, [255]McLaughlin Centre, University of Toronto, Toronto, ON, Canada, [256]Beyster Center for Psychiatric Genomics, University of California San Diego, La Jolla, CA, USA, [257]Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA

*Correspondence at jsebat@ucsd.edu

Abstract

Rare copy number variants (CNVs) are a key component of the genetic basis of psychiatric conditions, but have not been well characterized for most. We conducted a genome-wide CNV analysis across six diagnostic categories (N = 574,965): autism (ASD), ADHD, bipolar disorder (BD), major depressive disorder (MDD), PTSD, and schizophrenia (SCZ). We identified 35 genome-wide significant associations at 18 loci, including novel associations in SCZ (*SMYD3*, *USP7-HAPSTR1*) and in the combined cross-disorder analysis (*ASTN2*). Rare CNVs accounted for 1–3% of heritability across diagnoses. In ASD, associations were uniformly positive, consistent with autism having diverse etiologies and clinical presentations. By contrast, CNVs showed a dose-dependent relationship for other diagnoses, including SCZ and PTSD, with reciprocal deletions and duplications having inversely correlated effects and distinct genotype-phenotype relationships. Our findings suggest that genes have effects that are both dose-dependent and pleiotropic, such that a positive influence on one dimension of psychopathology may be accompanied by positive or negative effects on others.

Introduction

The genetic architecture of neuropsychiatric traits is highly polygenic and consists of a wide range of allelic effects, from common variants of small effect [1,2] to rare variants of large effect [3-5]. In particular, rare copy number variants (CNVs) have provided key insights into the etiology of psychiatric conditions [3]. Aggregate measures of rare CNV burden provided the earliest evidence for the contribution of rare variants to autism spectrum disorder (ASD) [6] and schizophrenia (SCZ) [7,8], and studies of rare variants are beginning to make progress in major depressive disorder (MDD) [9] and post-traumatic stress disorder (PTSD) [10]. In addition, genome-wide association studies of rare CNVs have been vital for the discovery of genes and molecular pathways underlying psychiatric conditions. Analysis of CNVs within genes has implicated pathways involved in chromatin regulation [11] and synaptic function [12,13]. Studies in larger samples have found strong associations of specific rare CNVs with ASD [14,15] and SCZ [16-19]. Subsequent whole exome sequencing studies of ASD [16-18] and SCZ [5] have identified a wider array of rare gene mutations that further implicate pathways in synaptic function and genetic regulation of fetal brain development.

Despite these discoveries, the relationship of genes to the broad spectrum of psychiatric traits is not well defined. No rare variant has yet been found that is specific to a psychiatric diagnosis. Each rare CNV is associated with a variety of mental health and neurodevelopmental conditions [20] and cognitive [21,22], physical [23,24] and general medical [25] conditions in the general population. These findings are consistent with significant genetic overlap between diagnostic categories, and are consistent with rare variants being pleiotropic, i.e. each having variable expressivity for multiple psychiatric traits [26,27].

Large scale collaborative studies of CNV have the potential to identify novel gene associations and new targets for development of therapeutics. Furthermore, a cross-disorder approach, in which a comparative analysis is done for several psychiatric conditions in parallel, could give a more granular dissection of genotype-phenotype relationships in genes and pathways. Genome-wide association studies (GWAS) are being applied on a large scale to characterize common variant influence and shared genetic risk factors across multiple psychiatric conditions [28] in the Psychiatric Genomics Consortium (PGC). Here we apply the large-scale collaborative approach of the PGC to the discovery and characterization of rare variants that influence mental health by genome-wide analysis of CNVs in 574,965 individuals across six diagnostic categories.

Results

Rare CNV GWAS identifies 35 genome-wide significant associations at 18 loci.
We aggregated microarray intensity files from GWAS datasets to obtain rare CNV calls in 574,965 individuals (**Table S1**) including population controls (N = 441,958) and cases of SCZ (N = 36,865), ASD (N = 13,545), BD (N = 23,119), MDD (N = 38,917), PTSD (N = 17,839), and ADHD (N = 3,544). Individuals spanned multiple ancestries including 513,287 subjects classified as european (EUR), 27,964 asian (ASN/ASAM), 17,606 african (AFR/AFAM) samples, 5,812 Latin-X (LAT), and 10,296 subjects of mixed ancestry (**Table S2**). CNVs were called using a centralized pipeline for systematic CNV calling across genotyping platforms and cohorts. QC of the dataset was performed at the levels of samples

(**Fig. S1**), CNV calls, and probes, as described in the methods. Probe normalization methods and CNV calling accuracy are optimal for rare variants and a majority of common CNVs are captured by SNPs [29] ; thus, the call set was restricted to CNVs with frequencies <2%.

To identify rare genomic loci that contribute to psychiatric conditions, a CNV GWAS was performed in each group: ASD, ADHD, SCZ, PTSD, MDD, BD as well as in the combined cases, referred to as the cross-disorder group (XD). Statistical association tests were performed for CNV counts in cases and controls at each probe with a CNV across the genome by logistic regression, controlling for cohort, sex and ancestry principal components (PCA in **Fig. S2**). Summary statistics were generated separately for each genotyping platform. Meta-analysis of probe-level summary statistics on CNV associations was performed with METAL [30]. Parameters for meta-analysis were optimized to control for statistical confounders of CNV GWAS, including heterogeneity of genotyping platforms and sparse data on rare variants (**Fig. S3**). Genome-wide multiple test correction was estimated by permutation in the SCZ cohort to determine the appropriate threshold (Jaccard index) for collapsing correlated adjacent probes to estimate the genome wide correction for each diagnostic category (**Fig. S4**). CNV GWAS was carried out for deletions (DEL) and duplications (DUP) separately in each diagnosis and in the combined XD cohort. Association analyses identified 35 genome-wide significant associations for 18 independent CNV loci (**Fig. 1a**, **Table S3**).

These results demonstrate a broad set of CNV associations that meet genome-wide significance for ASD, SCZ, BD or XD samples. These include many DELs or DUPs that are routinely reported in clinical genetic testing [31,32] , including CNVs at 1q21.1[33], 3q29[34], 16p11.2 [35], 22q11.2 [36] and several others (**Table S3**). In addition, we find novel associations with CNVs not established previously as causal variants for psychiatric traits. Gene duplications of *SMYD3* were associated with SCZ in this study and have not been described elsewhere in the clinical genetics literature. DELs of *ASTN2* reached genome-wide significance in the XD cases, consistent with *ASTN2* loss of function having a broad association with multiple psychiatric conditions [37,38]. Duplications of the genes *USP7* and *HAPSTR1* showed a novel association with SCZ in this study.

CNV alleles at five loci showed genome-wide significant associations with more than one diagnosis (1q21.1, *NRXN1*, 15q11.2 BP1-BP2, 15q11.2-13.1, 16p11.2 proximal, **Table S3**) and three reached genome-wide significance only in the XD cohort (*ASTN2*, 16p13.11, 16p12.2 BP2-BP3). These results are consistent with the well-documented pleiotropy of psychiatric risk alleles [3,20] and the corresponding overlap in the genetic basis of different psychiatric conditions. [1,20,28] For example, a large DUP of 15q11.2-13.1, one of the most well documented rare variants associated with ASD [39], is also significantly associated with SCZ (**Fig. 1b, green**), and smaller DELs of this region, 15q11.2 (BP1-BP2/CYFIP1) DEL[19] and 15q13.3 DEL[8,19], were also associated with SCZ (**Fig. 1b**). 16p13.11 DEL and 16p12.2 DEL were associated with XD (**Fig. 1c, gray**) while reciprocal DELs and DUPs of 16p11.2 proximal show contrasting associations, the DEL being most significantly associated with ASD [14] and the DUP most significantly associated with SCZ [16] as well as BD and ASD (**Fig. 1c**).

Figure 1: Detection of 35 genome-wide significant associations at 18 loci. *A) CNV GWAS was performed at the breakpoint level. CNV GWAS Manhattan plots for all individual disorders were superimposed on top of each other to produce a porcupine plot of all associations in 6 diagnostic categories and in XD. The black line shows the approximate genome-wide significance threshold (DUP: 3.2x10⁻⁵, DEL: 2.5x10⁻⁵) since the threshold varies by diagnosis. The genome-wide significance thresholds for the 7 groups are ASD (DUP: 4.9x10⁻⁵, DEL: 3.5x10⁻⁵), ADHD (DUP: 4.9x10⁻⁵, DEL: 3.4x10⁻⁵), SCZ (DUP: 4.1x10⁻⁵, DEL: 3.0x10⁻⁵), PTSD (DUP: 4.7x10⁻⁵, DEL: 3.4x10⁻⁵), MDD (DUP: 4.4x10⁻⁵, DEL: 3.1x10⁻⁵), BD (DUP: 4.3x10⁻⁵, DEL: 3.1x10⁻⁵), and XD (DUP: 3.2x10⁻⁵, DEL: 2.5x10⁻⁵). The directionality of effect for each genome-wide significant hit is indicated by upward (positive) and downward (negative) facing triangles. B) Zooming into the cluster of associations on chr15 shows how psychiatric associations differ substantially between CNVs. SCZ is strongly associated with DELs in 15q11.2 and 15q13.3. In contrast, a DUP spanning 15q11.2-13.1 has its strongest association with ASD and to a lesser extent SCZ. C) Zooming into the cluster of associations on chr16 shows how CNV type can result in different psychiatric outcomes within a locus. A DUP at 16p11.2 proximal is strongly associated with SCZ while a DEL in the same location is strongly associated with ASD* **Table S3**.

Rare CNVs explain 1-3% of the heritability in all diagnostic categories.

We and others have shown that the genome-wide burden of CNVs is a significant contributor to ASD and SCZ [6–8,13]. Conversely, reports of weak associations of CNV burden with BD [40,41], MDD[42], and PTSD [10] imply that rare variants could have a comparatively small contribution to the genetic basis of other psychiatric conditions with adult onset. The combined frequency of CNVs at 18 genome-wide significant loci are present in 1.6-3.1% of cases (**Fig. 2A, Table S4**) and 1.4% of controls.

Estimates of the total CNV burden genome-wide suggest significant disparities between diagnostic categories in the contributions of rare variants. The burden of risk alleles (genome-wide significant) was increased in ASD and to a lesser extent in SCZ, BD and MDD; however the collective frequency of risk alleles in ADHD and PTSD was not significantly greater than in controls (**Fig. 2A**). The total variance explained by CNV burden (length) was estimated by meta-analysis of Nagelkerke's R^2 estimates from logistic regression. As

expected, variance explained by genome wide burden was greatest for ASD (R^2=0.86%) and
SCZ (R^2=0.28%) and weaker for BD (R^2=0.11%), ADHD (R^2=0.07%), MDD (R^2=0.03%),
PTSD (R^2=2.78x10^{-5})(**Fig. 2B**, **Table S5**). When we dissected CNV burden by functional
categories of length (bp), large CNVs (>1 Mb), and loss of function intolerance (pLI>0.5),
CNV burden for all diagnoses was increased in one or more functional categories (**Fig. S5,**
Table S6). We found modest evidence for a reduced CNV burden in loss-of-function
intolerant genes in PTSD relative to controls (**Table S6**). This weak effect could imply that
some rare variants reduce the probability of a PTSD diagnosis or it might be consistent with
case ascertainment of some PTSD cohorts selecting against traits attributable to deleterious
variants in genes (such as intellectual disability).
482
There was less disparity between diagnostic categories in the contribution of rare variants,
when we quantified variance explained by CNV genotype rather than their collective
burden. Estimation of Nagelkerke's R^2 from logistic regression finds that CNVs at
genome-wide significant loci explain 0.2-1% of the variance across all 6 diagnostic
categories (**Fig. 2B, Table S5**). An additional 0.2-0.3% was explained by other
clinically-reportable CNVs [21,43] (**Table S7**) that were not genome-wide significant in our
study (**Fig. 2B, Table S5**). In total, the variance explained by CNV genotypes and
genome-wide burden combined was non-trivial in all disorders and ranged from 0.6% to
2% **(Fig. 2B, Table S5).** Transformation of the Nagelkerke's R^2 to a liability scale gives
heritability estimates of 0.9% to 3% (**Table S8**).
493
When the six diagnoses were ranked based on the variance explained by rare CNVs (ASD >
SCZ > ADHD > BD > MDD > PTSD), the R^2 estimates in this study were correlated with
corresponding estimates of heritability from twin studies (Spearman's rank correlation P =
0.0028, **Table S8**). However, when R^2 was converted to a liability scale, the correlation with
twin heritability was not significant (p = 0.48) and neither estimate was strongly correlated
with current estimates of SNP-based heritability (**Table S8**). Given that heritability
estimates rely on estimates of diagnosis prevalence that have been changing over time [44,45],
we regard our estimates of Nagelkerke's R^2 to be a more accurate representation of the
relative contributions of rare variants across the six diagnostic categories.
503

Figure 2: Rare CNVs span a broad range of frequencies and effect sizes, and explain 0.6-2% of the variance in all diagnostic categories. (A) Frequencies of CNVs in 6 diagnostic categories, **Table S4***. (B) Variance explained by rare CNV genotype (R^2) in each diagnosis was estimated for the combined loci by logistic regression. Loci were stratified for each diagnosis into genome-wide significant loci, and "other" known pathogenic microdeletion and duplications that are routinely reported in clinical genetic testing but do not reach genome-wide significance in this study. Diagnoses are ordered according to their ranking in the "Combined Genotype and Genome Wide Burden". Total variance explained by rare CNV was as follows: PTSD (R2=0.58%), MDD (R2=0.74%), BD (R2=0.81%), ADHD (R2=0.85%)m SCZ (R2=1.11%), and ASD (R2=2.08%), results in* **Table S5***. (C) Effect sizes of significant loci in the CNV-GWAS are shown as a function of frequency. There was an average of 50.7 independent tests in each diagnostic category. Effect sizes are given for all CNVs that show at least one association that meets BH-FDR≤10% correction (open circles) In addition, all associations that meet Bonferroni correction for 50 tests (P≤0.001) or meet genome-wide significance are shown (see Methods) (solid circles). Effect sizes for significant SNPs from previous SNP-GWAS were included to model variation effects across the full frequency spectrum. Results for DEL and DUP effect sizes at 18 loci are in Supplementary* **Table S9***.*

Characterizing pleiotropic effects of CNVs across 6 diagnoses

To gain a more complete view of the spectrum of diagnoses associated with each CNV, we estimated the effect sizes for specific CNV alleles within 18 genome-wide significant loci across 6 diagnostic categories. Within each association peak, distinct CNV alleles with recurrent breakpoints were delineated (**see Table S9**). At association peaks where breakpoints were not recurrent (i.e. were randomly distributed), individual genes were tested (*SMYD3* at 1q44, *ASTN2* at 9q33, *USP7* and *HAPSTR1* at 16p13.2, and *DLGAP2*, *MYOM2* and *CSMD1* at 8p23). We included all tests for which there were at least 12 CNVs in the combined sample. In total, 50 alleles or genes were tested across 6 diagnoses, and 67 associations were found at a false discovery rate (BH-FDR) ≤ 10%. (**Table S9**). **Figure 2C** displays a trumpet plot of effect size vs frequency, combining rare CNV with common SNP associations from the summary statistics of the PGC GWASs of ASD [46], SCZ [47], BD [48], MDD [49], PTSD [50], and ADHD [51]. Curves for each group were fitted to an exponential model to provide a unified representation of rare and common variants. (**Fig. 2C**).

Nearly all loci identified in this study show evidence of association with multiple diagnoses, consistent with genes having pleiotropic effects on psychiatric traits [20]. ASD is notable for having many rare variants with large effects, all of which are in the positive direction (associated with cases). By contrast, the genetic architecture of other diagnoses consists of a mixture of positive (higher rate in cases) and negative associations (higher rate in controls). The negative associations that were observed, however, do not represent "protection" from all mental health conditions. Without exception, all CNV alleles that had a negative association with one diagnosis also had a positive association with another in this study (15q11.2 BP1-BP2 DEL, 22q11.2 A-D Dup, CSMD1 DEL) or in previous studies (16p13.11 BP1-BP2 DUP[52], 22q11.2 B-D DUP[53]), consistent with the same gene(s) having divergent effects in different disorders.

Genes have dose-dependent effects on psychiatric traits

DELs and DUPs of the 22q11.21 A–D region show opposing associations with schizophrenia (SCZ), with DELs increasing susceptibility and DUPs decreasing it [54], and both associations reached genome-wide significance in this study. In addition, across all CNVs, the effect sizes of reciprocal DELs and DUPs for SCZ were inversely correlated (**Fig. 3A**), consistent with a linear dose-response relationship. A similar inverse correlation was observed for PTSD (**Fig. S6**). Despite having numerous strong associations, this inverse relationship was not evident for ASD where the DEL-DUP correlation was weakly positive (**Fig. 3B**). The contrasting dose-response curves for SCZ and ASD highlight key differences between these diagnostic categories. With respect to the opposing effects of DEL and DUP, the diagnostic category of SCZ is generally associated with one or the other, whereas the diagnostic category of ASD is often associated with both.

Analysis of the pairwise genetic correlations of diagnostic categories based on CNV effect sizes (**Table S9**) shows a significant genetic correlation of SCZ and BD (**Fig. 3C, Table S10,** $p=3.32 \times 10^{-6}$). Weak correlations were also observed between these disorders and ADHD (BD p-value=0.01, SCZ p-value=0.02) and between MDD and ASD (p=0.03). The genetic correlations that we observe for CNVs are consistent with genetic correlations observed in GWAS [1,28]. The notable absence of correlation for SCZ and PTSD highlights how the

566 dose-dependent relationships of genes is evident for both disorders (**Fig. S6**) despite
567 having different associations with specific loci.
568
While nearly all CNVs were associated with multiple diagnoses, this was not a reflection of
rare variant effects being highly non-specific. To the contrary, different alleles exhibited
different spectra of associations. Some loci show contrasting phenotype associations for
reciprocal DEL and DUP of the same genes including 15q11.2 BP1-BP2 (**Fig. 3D**), 16p11.2
BP4-BP5 ("proximal 16p", **Fig. 3E**), 22q11.2 A-D (**Fig. 3F**) and 22q11.2 B-D (**Fig. 3G**).
Results are consistent with these CNVs having dose-dependent effects on psychiatric traits,
and within the 22q11.21 CNV, the dose-dependent effect may be driven by genes within the
B-D locus.
577

✴ BH-FDR ≤ 0.1   ✴✴ Bonferroni significant   ✴✴✴ Genome-wide significant

578
579 ***Figure 3****: Dose response curves show inverse correlation of effect sizes for deletion and duplication in (A) SCZ, but not (B)*
580 *ASD. (C) Pairwise genetic correlations of six disorders based on CNV associations, see* ***Table S10****. (D-G) Effect sizes of deletion*

At other loci where breakpoints were not recurrent, we compared the effect sizes for
multiple genes within the same association peak. Within 8p23 for example, DELs of *DLGAP2*
have a strong association with ASD, while DELs of nearby *CSMD1*, a gene that has been
previously implicated in GWAS [2,55] show contrasting associations with mood disorders BD
and MDD (**Fig. 3H**). Within 16p13.2, DUPs of *USP7* are associated with ASD and MDD, while
the genome-wide significant association of DUPs with SCZ appears to be strongest for the
adjacent *HAPSTR1* gene (**Fig. 3I**). Radar plots of effect sizes for DELs and DUPs across 6
diagnostic categories are shown for all loci tested (**Fig. S7, Table S9**).

Relationships of CNV genotype to phenotype that are observed here are attributable to the
dose-dependent effects of genes on pathways and cellular processes As described in our
companion paper [56], the diagnostic categories of schizophrenia, autism and mood disorders
can be differentiated based on the gene-dosage effects on pathways stratified by cell-type
and brain region. In particular, 16p11.2 BP4-BP5 and 22q11.2 A-D are enriched for distinct
cellular processes that are characteristic of the DUP and DEL effects respectively that
contribute to SCZ. Thus the spectrum of clinical phenotypes observed for CNVs in Figure
3E-F is a reflection of how pathway effects are concentrated in neural cell types and cortical
brain regions [56].

Recurrent mutations in large neural genes highlight novel associations
Without exception, all associations found in this study occurred in genomic regions that are
prone to high rates of structural mutation. Twelve loci consist of hot-spots for non-allelic
homologous recombination (NAHR)[57] that have recurrent breakpoints, in most cases span
multiple genes, and are given a cytoband-breakpoint label in **Figure 2** (e.g. 1q21.1) to
reflect the CNV allele that was tested. The remaining six loci were common fragile sites
(CFS) where double strand breaks occur with high frequency and are distributed more
randomly. [58] CFS loci are labeled with gene symbols to reflect the genes that were tested
(*ASTN2*, *NRXN1*, *SMYD3, SHANK3, DLGAP2-CSMD1*, *USP7-HAPSTR1,* **Table S3**). The fact that
all associations occur within CNV hotspots is consistent with the statistical power for rare
variants being greatest for the loci with the highest mutation rates [59].

All three single-gene associations consist of fragile sites within long genes that have
functions related to neuronal development [58]. Long genes are prone to replication stress,
and consequently, genome instability [60], and tend to co-localize with TAD boundaries[61].
These include positive associations of *NRXN1* DELs in SCZ (**Fig 4A**), *ASTN2* DELs in XD (**Fig.
4B**) and *SMYD3* DUPs in SCZ (**Fig 4C**). CNVs in these genes have a characteristic fragile-site
signature where the breakpoints, lengths and functional consequences of the CNVs are
variable. When we stratified CNVs by predicted functional consequence, the associations of
NRXN1 and *ASTN2* DELs were greatest for loss-of-function (LoF) variants that are predicted
to result in truncation of the protein (**Table S11**). The association of *SMYD3* DUPs was
driven by variants that span at least one full length transcript of the gene, consistent with a
gain of function effect (**Table S11**).

Figure 4: CNV associations implicate large neural genes within common fragile sites. *Three genome-wide significant loci that overlap fragile sites and TAD boundaries from Dorsolateral Prefrontal Cortex (DLPFC TADs) are shown for A) NRXN1 B) ASTN2 and C) SMYD3. Association tests (bottom) were stratified by predicted functional consequence: loss of function (LOF), In frame, and intronic (Intron). Duplications spanning a full length isoform (Full Iso) or partially spanning an isoform (Part Iso), and intronic (Intron).* **Table S11**.

Recurrent duplications of *SMYD3* are associated with schizophrenia

The association of the gene SET and MYND domain containing 3 (*SMYD3*) with SCZ appears to be driven by DUPs of full length transcripts, suggesting that the causal variants increase the number of functional copies of *SMYD3*. However, gene duplications detected by microarray can have hidden complexity that, in some cases, results in loss rather than gain of function[62]. To clarify the structure and functional consequence of *SMYD3* DUPs, DNA samples from 3 carriers with DUPs spanning the short isoform of *SMYD3* were obtained from DNA samples available to our group through UCSD and collaborators at Trinity College Dublin, and HiFi long-read whole genome sequencing was performed on each sample using the Pacific Biosciences Revio platform to a total coverage of >20X (**Fig. 5A, Table S12 for coverage and QC**). HiFi long reads were aligned to both the GRCH38 and CHM13 assemblies using PBMM2, and SVs were called using Sniffles and LUMPY. In each genome, DUP breakpoints were identified and contigs were assembled from breakpoint-spanning reads using Flye v2.9.2. Assembled breakpoints revealed that each SV had a distinct structure. Subject 1 carried a tandem duplication of 666,289 bp spanning the short isoform of *SMYD3* (ENST00000403792.7, **Fig 5B**). Subject 2 carried a 516,050 bp non-tandem duplication of ENST00000403792.7 that was inserted into the first intron of *OR2G6* (**Fig 5C**). Subject 3 carried a tandem duplication of 1.6 Mb spanning >10 genes including the full length of the *SMYD3* gene (**Fig 5D**). Thus, all DUPs appear to result in an increased copy number of at least one full length isoform of *SMYD3*.

All breakpoint positions were non-recurrent (unique to each subject). In two cases, tandem duplications resulted in the partial duplication and recombination of genes near the breakpoint junction. However, the fused transcript pairs *CNST*/*SMYD3* (**Fig 5B**) and *KIF26B*/*ZNF496* (**Fig. 5D**) were on opposite strands. In patient 3, the *SMYD3* gene is inserted within *OR2G6* (**Fig 5C**) in the same orientation, and is predicted to fuse exons 1-5 of the long isoform of *SMYD3* with the full open reading frame of *OR2G6*. Thus, in addition to duplicating the short isoform of *SMYD3*, the SV has the potential to cause ectopic expression of an olfactory receptor from the *SMYD3* promoter.

Figure 5: Structures of SMYD3 duplications resolved by HiFi long read WGS

(A) The association peak spans exons 1-3 of the SMYD3 gene while the CNVs themselves have variable breakpoints that duplicate different nearby genes. Pacbio sequencing was performed on 3 cases with the SMYD3 Dup and the corresponding microarray CNV calls are shown (green) on the SCZ DUPs track. (B) The first sample is a tandem duplication that spans the full short isoform of SMYD3. The duplicated portion truncates the long isoform of SMYD3 on the proximal side as well as the CNST gene on the distal side. The inserted sequence has portions of both CNST and SMYD3 sitting flush with each other. (C) The next sample is an inserted DUP that spans the full short isoform of SMYD3. It does not include any extra genes and is inserted next to the olfactory receptor genes with a small deletion of 393bp. (D) The last sample is another tandem duplication that spans all isoforms of SMYD3. It is a longer DUP that includes many genes on the distal side of SMYD3. This DUP cuts KIF26B on the proximal side of SMYD3 and ZNF496 on the distal side and the resulting genome in the sample has both genes sitting flush with each other. **Table S12***.*

Discussion

In a comparative study of rare CNVs across six psychiatric diagnoses (ASD, ADHD, SCZ, BD, MDD, and PTSD), rare variant associations elucidate key aspects of the genetic architecture. This study identified 35 genome-wide significant associations at 18 different CNV regions, providing a map of loci where gain or loss of gene dosage influences psychiatric traits. This represents a 4-fold increase in the number of CNV associations to date that meet genome-wide significance in the PGC [13].

Rare CNVs accounted for 0.6–2% of the variance in case status across 6 diagnostic categories, corresponding to 0.9–3% of liability-scale heritability. This contribution is independent of the heritability explained by common variants. ASD is notable for having

many rare variants with large effects, all of which are in the positive direction. For other
diagnostic categories, such as SCZ, BD and MDD (Fig. 2C), the contribution of rare variants
consisted of a mixture of risk alleles (more frequent in cases) and protective alleles (more
frequent in controls). Hence, the genome-wide burden of rare variants in a categorical
diagnosis is not a particularly accurate measure of their influence. The collective frequency
of rare CNVs in some disorders, such as ADHD and PTSD, is similar to the frequency in
controls but CNVs still account for approximately 1% of heritability.
697
Importantly, the negative associations that we observe do not represent broad "protection"
from mental health conditions. Without exception, all CNV alleles that had an effect size
that was negative for one diagnosis have a positive association with another in this study
(15q11.2 BP1-BP2 DEL, 22q11.2 A-D DUP, CSMD1 DEL) or in previous studies
(16p13.11BP1-BP2 DUP[52], 22q11.2 B-D DUP[53]), highlighting how the same CNV allele can
have divergent, sometimes opposing, associations with different psychiatric traits.
704
Furthermore, different CNV alleles have different spectra of associations across 6
diagnoses. These contrasts are particularly evident for reciprocal DEL and DUP of the same
genes (**Fig. 3**). Previous studies have shown that CNVs have "mirror" dose-dependent
effects on a variety of complex traits [23,24], including brain structure [63] and cognition [64,65].
Here we show that this principle also applies to psychosis and other psychiatric traits.
Reciprocal DELs and DUPs of 22q11.21 show opposing positive and negative associations
with schizophrenia (SCZ) respectively [54]. Furthermore, across all loci, there was an inverse
correlation of effect sizes for reciprocal CNVs in SCZ and PTSD, suggesting that CNVs have a
dose-dependent relationship with some diagnoses. ASD, by contrast, was characterized by a
neutral (weakly positive) dose-response curve. Thus, with respect to the opposing effects of
DEL and DUP, SCZ is generally associated with only one of the two extremes, but both often
fall under the diagnostic umbrella of ASD. MDD showed a similarly neutral dose-response
curve (**Fig. S6**), and ASD and MDD exhibited significant genetic correlation (**Fig. 3C**). These
findings underscore how mental health traits related to social behavior and mood are
characterized by substantial clinical and genetic heterogeneity [66]. Deeper clinical
characterization of dimensional cognitive phenotypes associated with reciprocal CNVs
could better elucidate relationships of gene dosage with quantitative traits and could help
to dissect the clinical and genetic heterogeneity within these diagnostic categories [67].
723
Multiple novel loci were identified in SCZ (*SMYD3*, *USP7-HAPSTR1*) and in the combined XD
sample (*ASTN2*). SET and MYND domain-containing protein 3 (*SMYD3*) is a histone
methyltransferase expressed predominantly in the brain [68] with a function in chromatin
regulation [69]. While it's role in regulation of neural function is not known, a recent study has
shown that *SMYD3* expression is elevated in the prefrontal cortex of patients with
Alzheimer's disease, and a SMYD3 inhibitor rescues synaptic and cognitive deficits in a
mouse model of tauopathies [70]. A variety of inhibitors of *SMYD3* have been developed in
oncology [71]. Thus, validation of increased *SMYD3* dosage as a risk factor for psychosis could
offer a potential avenue for development of new therapeutics. DUPs that span *USP7* and
HAPSTR1 were associated with SCZ in this study. More detailed characterization found
evidence that the *USP7* gene was associated with ASD and MDD, consistent with recurrent
de novo DUPs of this region previously reported in ASD [72]. Ubiquitin-specific protease 7

(*USP7*) is a deubiquitinating enzyme that is highly expressed in neuronal cells in cerebrum, cerebellum, and hippocampus[73]. *USP7* influences neuronal development and function through neuronal migration [74], dendritic spine morphogenesis[75] and neuroinflammation.[76] The SCZ association with this locus was strongest for the adjacent gene *HAPSTR1* (**Table S9**), which encodes a regulator of stress response pathways [77], which have been implicated in the etiology of SCZ [78]. DELs of *ASTN2* were significant in the combined XD cases suggesting these confer risk for a broad range of psychiatric disorders. This finding is consistent with previous reports of *ASTN2* DELs in small samples of SCZ, BD and ASD [37,79]. *ASTN2* is predominantly expressed in the brain and plays a role in neuronal migration [80] and synaptic function [81]. Common SNPs within *CSMD1*[82] and *NRXN1*[2] are associated with SCZ, and *ASTN2* has been implicated in GWAS of MDD[83] and BD[84]. Thus, a convergence of evidence from both rare and common variants implicate the same genes. Synaptic neurotransmission, regulation of synaptic plasticity, chromatin and post-transcriptional regulation are common threads between studies of CNVs, whole exome sequencing [5] and GWAS [85]. A more detailed characterization of the molecular pathways, cell types and brain regions that are implicated by CNV associations is described in our companion paper [56].

A majority of the CNVs that reached genome-wide significance in this study are variants that are routinely reported in clinical microarray (CMA) testing, and clinically-reportable CNVs that did not reach genome-wide significance in this study explained another 0.2-0.3% of the variance across all six diagnoses (see **Table S5**). Yet very few of the subjects enrolled in this study have been offered genetic testing as part of their clinical care. CMA has historically been restricted to pediatric populations for the evaluation of congenital malformations[86], intellectual disability and autism [87], and insurance providers approve it only for these indications. Consequently, the clinical features of CNVs that are described in the literature reflect this bias, and may not be representative of clinical presentations of CNV carriers in the broader adult population [25,88]. As large-scale studies like this one begin to uncover associations between CNVs and adult-onset health conditions, the effectiveness of early tailored interventions can be evaluated, clinical guidelines can be revised, and the need for genetic counseling in subjects carrying these CNVs can be assessed. When considering all clinically-reportable variants that influence mental health, the overall difference in diagnostic yield between different clinical populations is relatively small (**Fig. 2A**). If the rationale for ordering a clinical genetic test is the utility of genetic information for lifelong clinical management and genetic counseling of individuals, then the utility of CMA is not limited to the pediatric developmental clinic.

Acknowledgements

We thank the many research participants. The PGC is supported by grants to UCSD (R01MH124847), UNC (R01MH124871), MGH (R01MH124851), Mount Sinai School of Medicine (R01MH124839), Cardiff University (R01MH124873), Trinity College Dublin (R01MH124875) and Washington University St. Louis (R01DA054869). Additional support was provided by grants to J.S. (MH119746, MH133899), C.N. (MH106595, MH124847) and S.J. (U01 MH119690, U01 MH119739, CIHR_495906). Funding for the work in Bipolar Disorder was supported by the Research Council of Norway (#223273, 248778, 262656, 273291, 283798, 248828), South East Norway Health Authority (2017-112), and KG Jebsen Stiftelsen. The iPSYCH project is supported by grants from the Lundbeck Foundation

(R165-2013-15320, R102-A9118, R155-2014-1724 and R248-2017-2003) and the universities and university hospitals of Aarhus and Copenhagen. Genotyping of iPSYCH samples was supported by grants from the Lundbeck Foundation, the Stanley Foundation, the Simons Foundation (SFARI 311789 to M.J.D.), and NIMH (5U01MH094432-02 to M.J.D.). The Danish National Biobank resource was supported by the Novo Nordisk Foundation. Data handling and analysis on the GenomeDK HPC facility was supported by NIMH (1U01MH109514-01 to A.D.B.). High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus University, Denmark (grant to ADB).

Data and code Availability

A WDL workflow containing all steps of CNV calling, QC and CNV-GWAS and meta-analysis code is under construction and will be released on the PGC CNV Github in conjunction with this publication (https://github.com/orgs/psychiatric-genomics-consortium/teams/cnv).

Meta-analysis of summary statistics for 6 diagnoses and the combined XD sample will be released through the PGC downloads page
https://pgc.unc.edu/for-researchers/download-results/

Raw genotype and intensity files are available on subset of the cohort
PGC dbGAP datasets
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/collection.cgi?study_id=phs001254.v1.p1

Simons Foundation Autism Research Initiative SFARI (SSC and SPARK)
https://base.sfari.org/

Supplementary Materials and Methods

Methods

GWAS datasets of the PGC

The CNV subgroup of the Psychiatric Genomics Consortium (PGC) works in collaboration with principal investigators from many institutions to obtain large sample sizes of microarray data and analyze them using a centralized pipeline. We acquired microarray intensity files from GWAS for a total of 574,965 samples that included data from 6 psychiatric conditions (**Table S1**). These samples were genotyped on 25 platforms across 4 genome builds. Data from Illumina was collected as either raw intensity data (IDAT) files or final report files while data from Affymetrix was collected as CEL files. To harmonize data, probes for newly acquired datasets were lifted over to GRCH38 for CNV calling while previously called CNVs were lifted over to GRCH38. Samples were genotyped on either Illumina or Affymetrix array.

Copy number variant calling

For samples that were provided as IDAT files, the Illumina command line version of Genome Studio was used in conjunction with platform-specific manifest and cluster files to produce genotype call (GTC) files. Relevant features were extracted from GTC files to obtain final report files with probes, genotypes, Log R Ratio (LRR), and B Allele Frequency (BAF) for each sample. For samples that were not mapped to GRCH38, probe genome positions were converted to hg38 using the LiftOver tool. Samples within each platform were grouped into batches by plate. For Affymetrix 6.0 arrays, CNVs were called using four methods: PennCNV, iPattern, CScore, and Birdsuite. For Affymetrix 5.0 and 500K arrays, CNVs were called using two methods that were compatible with this platform: PennCNV and Birdsuite. For Axiom arrays, CNVs were called using PennCNV and QuantiSNP. For all Illumina arrays, CNVs were called using two methods: PennCNV and iPattern. The consensus of CNV calls from multiple callers was created by merging CNVs at the sample level and retaining CNVs that were called by at least 2 methods.

Quality control of samples and CNVs

Sample QC. Quality control (QC) was performed first at the sample level according to methods from our previous CNV GWAS of schizophrenia [13]. For Illumina arrays, LRR standard deviation, BAF standard deviation, and GC waviness factor were extracted from PennCNV log files (**Fig. S1**). Samples were retained if each of the measures were within 3 SD of the median. Affymetrix arrays used MAPD and waviness-sd parameters from affy power tools. The proportion of the chromosome that was tagged as a CNV was calculated and samples were excluded if >10% of the chromosome was marked as a CNV region to filter possible aneuploidies. Distribution of QC metrics differ by genotyping platform (**Fig. S1**), which provides a rationale for performing meta-analysis of summary statistics by platform.

CNV QC. A basic set of QC filters were applied to the call set, and subsequent filtering was performed at the probe level. CNVs that were called with different CNV types from different callers were excluded. Large CNVs that were fragmented were merged if one of the calling methods detected a CNV spanning the gap. CNVs < 10kb in length or contained < 10 probes were excluded. CNV calls were removed if they spanned the centromere or telomere (100kb from end of chromosome) or had >50% overlap with segmental duplications, immunoglobulin, or T cell receptor. Because the normalization of microarray intensity data is performed within a batch (typically a 96-well plate), CNV calling is optimal for rare CNVs that show distinguishable deviation in probe intensities relative to other samples within a plate. For common copy number polymorphisms (frequencies >10%), there is high variance in probe intensities within plates as well as sampling variance in the distribution of copy numbers. For this reason, CNV calling accuracy is suboptimal for common CNVs. Furthermore, a majority of common CNVs are tagged by adjacent SNPs [29] and are already captured by GWAS. Thus our final call set was restricted to CNVs with ≤ 10% frequency within-platform or across all platforms.

Probe QC. Our CNV-level QC applied a liberal threshold of 10% frequency to make certain that pathogenic CNVs near the rare CNV frequency boundary were kept in our analysis. CNV frequency was then calculated for each probe and probes with rare CNVs were kept if they contained ≤ 2% CNV frequency within-platform and within-dataset. Additionally, probes

were removed if they were heavily filtered by CNV QC (filtered CNVs > 20). Platform-specific and dataset-specific CNVs arose from the differing probe content of the many genotyping arrays. We applied probe-level specificity filters to prevent these CNVs from causing spurious associations in our results as described in detail in the Methods.

Ancestry principal components and ancestry partitioning

We extracted a subset of SNPs with < 1% missingness across all platforms (12,185 SNPs) and performed a principal component analysis using the flashPCA software [89]. In order to genetically infer the ancestry of each individual, we used the SNPweights software [90] on the same subset of SNPs to calculate % ancestry based on a reference panel containing 6 different populations (751 EUR, 687 EAS, 630 SAS, 568 AFR, 41 AMR, 22 OCE). Samples were categorized into 5 large homogeneous groupings based on the following criteria used in a previous study [50] (**Table S2, Fig. S2**): <u>EUR</u>: subjects with EUR ≥ 90%, <u>AFR/AFAM</u>: subjects with EUR < 90% & AFR ≥ 5% & EAS/SAS/AMR/OCE < 5%, <u>ASN/ASAM</u>: subjects with EUR < 90% & (EAS ≥ 5% or SAS ≥ 5%) & AFR/AMR/OCE < 5%, LAT: subjects with EUR < 90% & AMR ≥ 5% & EAS/SAS/AFR/OCE < 5%, NAT: subjects with EUR < 90% & AMR ≥ 60% & EAS < 20% & SAS < 15% & AFR/OCE < 5%, <u>MIX</u>: Uncategorized subjects. The LAT and NAT groups were combined into a single group with the overall <u>LAT</u> label.

Statistics for CNV genome wide association

The association of deletions or duplications with case status was tested by logistic regression, controlling for confounding variables such as sex, genotyping platform, and 10 ancestry principal components (PCs) derived from SNP genotypes (**Model 1**). A logistic regression using only the covariates was used as a null model (**Null Model 1**). Datasets containing families used a conditional logistic regression with an extra covariate corresponding to the family ID (**Model 2, Null Model 2**). A chi-square test was then performed on the 2 models to obtain a p-value. A meta-analysis weighted by sample size (N-weighted) was applied across all platforms using METAL [30]. Effective sample size (N_{eff}) was used to determine the contribution of each platform. Associations were conducted at the breakpoint level since our sample size provided enough CNVs to obtain sufficient power. A breakpoint was included in the analysis if it contained at least 12 CNVs.

$Model\ 1: aff \sim CNV + sex + PCs$
$Null\ Model\ 1: aff \sim sex + PCs$

$Model\ 2: aff \sim CNV + sex + PCs + strata(FID)$
$Null\ Model\ 2: aff \sim sex + PCs + strata(FID)$

$$N_{eff} = \frac{4}{(1/N_{cases}) + (1/N_{controls})}$$

Addressing statistical confounders in large-scale genome-wide meta-analysis of rare CNVs.

In our experience, the key statistical confounders that must be addressed when performing a genome-wide meta-analysis of rare CNVs across many cohorts are (1) heterogeneity in CNV detection due to SNP genotyping platform and (2) The sparse data (zero cell) problem

918 [91], where some loci produce summary statistics with very high standard errors in a subset
919 of the cohort due to zero counts in cases or controls.
920
<u>Heterogeneity of SNP genotyping platforms</u>
Population stratification, a common confounder in genome-wide association studies [92] can
be addressed in studies of rare variants by controlling for ancestry principal components
derived from SNP genotypes [93]. In large-scale collaborative studies of rare variants,
however, there is another major confounder that must be addressed: differences in variant
frequency between cohorts that is attributable to differences in the technology platforms
used for rare variant detection.
928
"Platform stratification" is a confound that is conceptually similar to population
stratification but is tied to genotyping/sequencing platform instead of ancestry. In
large-scale collaborative studies of CNVs, where datasets from multiple cohorts are
combined, differences in CNV frequencies between datasets can arise due to differences in
CNV detection by the genotyping platforms that are used with each cohort. For instance,
due to regional differences in probe coverage, a given CNV may be detected with greater
sensitivity by platform A than by platform B. When two datasets genotyped with platforms
A and B are combined, a false-positive association with the CNV can occur, particularly
when the relative proportions of cases and controls differ between datasets (**Fig S3**). Thus
"platform stratification" can artificially produce differences in CNV frequency between
cases and controls.
940
To identify signals that are potentially attributable to platform stratification, we derived a
measure for the platform or dataset specificity of CNV counts for a given probe. CNV
frequency is calculated within-platform and within-dataset (**Equation 1**). A weighted
deviance score (WDS) is then calculated for each platform/dataset (**Equation 2**) and a
specificity index (SI) is derived by taking the maximum of the WDS across
platforms/datasets (**Equation 3**). When calculating the SI score, all counts were used to
calculate E_i in Equation 2, but only platforms/datasets with >2 CNVs were included when
calculating the maximum in Equation 3. This prevented inaccurate SI scores being driven by
single counts in smaller sample sizes. A threshold value of SI>0.2 was chosen for platform
and SI>0.6 was chosen for dataset to flag probes that display platform stratification.
951

$Equation\ 1: CNV\ Frequency_i = \frac{C_i}{N_i}$

$Equation\ 2: WDS_i = \frac{C_i - E_i}{\sqrt{E_i N_i}}$

$Equation\ 3: SI = max(WDS_i)$

$E_i = pN_i; N_i: \#\ of\ samples\ on\ platform\ i; p = \frac{C}{N}$

$C_i: \#\ of\ CNV\ counts\ on\ platform\ i; E_i: Expected\ CNV\ counts\ on\ platform\ i$

$N: \#\ of\ total\ samples; C: \#\ of\ total\ CNV\ counts$

When association tests are performed across the combined SCZ sample in a single logistic regression model, the associations that arise cluster into groups based on the SI measure. Most associations in SCZ, including all well established "known" associations, are enriched among probes that have low SI. A second small cluster of probes can be seen with high SI (**Fig. S3A**). In a manhattan plot, these appear as distinct association peaks that persist even when platform is included as a covariate in the logistic regression model (**Fig. S3C**). These spurious signals are addressed by a meta-analysis of CNV summary statistics by platform as described below.

Sparse data problem
A major confounder in genome-wide association studies of rare variants is attributable to sparse counts of rare variants within subsets of the combined sample, where there can be zero values in cases and controls distributed across the cohort [91]. These zero values can lead to greatly inflated standard error estimates for specific loci in a subset of the summary statistics used in the meta-analysis. When meta-analysis was weighted by standard error, tests that yielded high standard error estimates (**Fig S3B,** SEM>1) contributed to many spurious associations throughout the genome (**Fig. S3D**).

Sample size-weighted meta-analysis of samples grouped by genotyping platform
Platform heterogeneity was adequately addressed when (1) samples were first grouped by genotyping platform, and meta-analysis was performed across platforms and (2) meta-analysis was weighted by the samples sizes of each platform instead of standard error. Following this workflow, the combined association data does not show strong signals that are driven by probes subject to platform heterogeneity or by probes that show high SE estimates in the combined sample (**Fig. S3E**).

Estimation of multiple test correction
The p-value threshold that gives a family-wise error rate (FWER) of 0.05 was calculated as an adjusted Bonferroni correction. The total number of tests was replaced with the total number of independent tests (Equation 4). Independent tests were counted after removing tests with >4% Jaccard index. The Jaccard index threshold was chosen by comparing multiple test corrections based on permutations in the SCZ cohort on chr1 with Bonferroni corrections at different Jaccard index thresholds (**Fig. S4**).

$Equation\ 4$: $Genome\ wide\ significant\ threshold\ (p\ value) = \frac{0.05}{\#\ of\ independent\ tests}$

Investigating the Pleiotropic effects of CNVs across 6 diagnostic categories
To investigate the full range of psychiatric conditions associated with each locus, we performed a more detailed characterization of the effect sizes of specific CNV alleles across the 6 diagnostic categories. For each locus with recurrent (NAHR) breakpoints (1q21.1-21.2, 3q29, 7q11.23, 15q11.2, 15q11.2-13.1, 15q13.1, 15q13.3, 16p13.11, 16p12.2, 16p11.2, 22q11.21), we identified all of the distinct alleles within each locus and genotyped each individually. For loci with non-recurrent (randomly distributed) breakpoints (ASTN2, NRXN1, SMYD3, USP7-HAPSTR1, 8p23, 22q13.3) we tested individual genes. Altogether, across the 18 regions listed above, there were 43 distinct loci, and DEL and DUP were tested for each (86 alleles, **Table S9**).

Only tests with a count of at least 12 in the combined cases and controls were considered, thus ~50 tests are reported for each diagnostic category.

Annotating which CNV loci are recurrent (NAHR) or non-recurrent, and annotating clinically reportable CNVs

All of the associations reported in this study were "CNV hotspots", i.e. loci that are prone to genomic instability. A majority were "NAHR" loci where recurrent de novo CNVs occur by non-allelic homologous recombination (NAHR) and de novo mutation events produce deletions and duplications with similar breakpoints [57,94]. The remaining loci consisted of "fragile sites" where frequent double strand breaks give rise to many non-recurrent deletions and duplications that have breakpoints that are more randomly distributed across the locus. **Table S7** provides a guide to which CNV loci are NAHR or are non-recurrent. Where applicable, we also include links to clinical guidelines for CNVs that are recognized as pathogenic and reported in clinical genetic testing.

Table S7 was prepared as follows. An initial "morbidity map" of the genome was created by Cooper et al. [43], identifying NAHR-mediated regions and characterizing their associations using large clinical microarray datasets from pediatric developmental disorder cases. This study has since become a standard reference list of known recurrent CNVs used by our group and others [21]. We created an updated version of the morbidity map from the union of loci from Cooper et al.[43], Kendall et al[21], and this study. Breakpoints were refined to facilitate genotyping of distinct CNV alleles. A majority of the loci in the morbidity map are known CNVs that are routinely reported in clinical genetic testing. Where appropriate, we provide a URL link to clinical guidelines from Gene Reviews[95], Clin Gen[96], OMIM [97] or other databases. In addition, we label the CNV alleles corresponding to "GWS loci" and "Other Clinically-Reportable CNVs" in **Figure 2A.**

Calling genotypes for each locus

NAHR CNVs were genotyped based on CNV calls with >50% reciprocal overlap with the locus. For complex loci with several breakpoints and multiple subregions (BP1-BP2, BP2-BP3, BP3-BP4...), such as 15q11-13 and 22q11, each subregion was genotyped using one-way overlap with CNVs, and specific alleles were called based on the subregions that were spanned by each CNV. For example, a DEL that spans 22q11.21 A-B, B-C, and C-D would be called "22q11.2 A-D".

For single genes, we tested counts for predicted loss of function (LoF) variants (DELs that intersect with exons) and for predicted gain of function (DUPs that span at least one full-length isoform. For single gene loci we also compared associations for intronic DELs and DELs predicted to cause LoF or an in-frame deletion (**Fig. 4**).

Testing association of genome-wide CNV burden

The CNV burden of deletions and duplications was tested by logistic regression, controlling for confounding variables such as sex, genotyping platform, and 10 ancestry principal components (PCs) derived from SNP genotypes. CNV burden was calculated for each platform to control for differences in probe coverage between different cohorts.

1049 SE-weighted meta-analysis was used to estimate CNV burden using METAL [30] since
1050 N-weighted meta-analysis does not provide effect sizes.
1051
For analysis of genome-wide CNV burden, the number of base pairs that overlapped a CNV
genome-wide was used as the independent variable (**Burden Model 1**) and CNV burden
was calculated by comparing it to a model that only contained covariates (**Null Model**).
CNV burden was also calculated for CNVs > 1Mb in size with the same approach (**Burden**
Model 2, Null Model). Genes were partitioned into two tiers according to their pLI score:
high pLI (T1; pLI>0.5) and low pLI (T2; pLI ≤0.5). CNV burden was calculated for all genes
(**Burden Model 3A, Gene Null Model**), Tier 1 genes (**Burden Model 3B, Gene Null**
Model), and Tier 2 genes (**Burden Model 3C, Gene Null Model**) while controlling for the
out-of-category genome-wide burden defined as the number of base pairs that do not
overlap with the gene category being tested. CNV burden was calculated for the GWS loci
(**Burden Model 4A, Null Model**), clinically-reportable CNVs (**Burden Model 4B, Null**
Model), and GWS loci + clinically-reportable CNVs (**Burden Model 4C, Null Model**)
categories by counting the number of CNVs an individual carried in each category.
1065
Burden Model 1: $aff \sim \# \ of \ base \ pairs \ overlapping \ CNV \ + \ sex \ + \ PCs$
Burden Model 2: $aff \sim \# \ of \ base \ pairs \ overlapping \ CNV > 1Mb \ + \ sex \ + \ PCs$
Burden Model 3A: $aff \sim \# \ of \ base \ pairs \ overlapping \ genes \ and \ CNV \ + \ OOC \ + \ sex \ + \ PCs$
Burden Model 3B: $aff \sim \# \ of \ base \ pairs \ overlapping \ T1 \ genes \ and \ CNV \ + \ OOC \ + \ sex \ + \ PCs$
Burden Model 3C: $aff \sim \# \ of \ base \ pairs \ overlapping \ T2 \ genes \ and \ CNV \ + \ OOC \ + \ sex \ + \ PCs$
Burden Model 4A: $aff \sim \# \ of \ CNVs \ overlapping \ GWS \ loci \ + \ sex \ + \ PCs$
Burden Model 4B: $aff \sim \# \ of \ CNVs \ overlapping \ clinically \ reportable \ CNVs \ + \ sex \ + \ PCs$
Burden Model 4C: $aff \sim \# \ of \ CNVs \ overlapping \ GWS \ \& \ clinically \ reportable \ CNVs \ + \ sex \ + \ PCs$
Null Model: $aff \sim sex \ + \ PCs$
Gene Null Model: $aff \sim OOC \ + \ sex \ + \ PCs$
1076
Estimation of CNV frequencies in each diagnostic category
As mentioned above, it is necessary to control for genotyping platform when estimating the
relative frequencies of CNVs in cases and controls. Thus, the CNV frequencies in cases for each
category in **Fig. 2A** were derived from the odds ratio estimates from meta-analysis of CNV
counts. We use the observed control frequency and the odds ratio from meta-analysis of CNV
burden across platforms (**Burden Model 4, Null Model, Table S6**) to produce an accurate
estimate of CNV case frequency (**Equation 5**).
1084
1085 *Equation* 5: $freq_{case} = \frac{OR * freq_{ctrl}}{1 + (freq_{ctrl} * (OR-1))}$
1086 $freq_{ctrl}$: CNV frequency in the combined control sample
1087
1088 **Total variance explained by CNVs**
1089 The proportion of variance explained by CNVs was determined by calculating Nagelkerke's
1090 R^2 between a CNV model and a null model. Nagelkerke's R^2 was calculated for each platform
1091 separately to control for differences in probe coverage between different cohorts.
1092 Bootstrapping was implemented to estimate standard errors for the R^2 estimate on each

platform and summary statistics were combined through meta-analysis using the *metafor* package in R [98].

Nagelkerke's R^2 was calculated for genome-wide burden of length, loci that were genome-wide significant in our study, clinically-reportable CNVs, and the combination of all categories. The R^2 estimate for genome-wide burden of length was tested by adding the length of all DELs and DUPs separately for each individual and comparing a logistic regression model of aggregate length and covariates (**Burden Model**) against a model with only covariates (**Null Model**). To estimate R^2 for the GWS loci and clinically-reportable CNVs, a genotype matrix was created for each category (separate genotypes for DEL and DUP) and a logistic regression model with each locus genotype as a separate variable plus covariates (**Genotype Model**) was compared against a model with only covariates (**Null Model**). The genotype matrix for GWS loci and clinically-reportable CNVs was then combined and supplemented with the genome-wide burden annotations (DEL and DUP) to estimate the R^2 for the combined genotype and genome-wide burden using the same method (**Combined model, Null Model**).

$Burden\ Model$: $aff \sim \#\ of\ base\ pairs\ overlapping\ DEL\ +\ \#\ of\ base\ pairs\ overlapping\ DUP$
$\quad +\ sex\ +\ PCs$
$Genotype\ Model$: $aff \sim CNV\ genotype\ +\ sex\ +\ PCs$
$Combined\ Model$: $aff \sim CNV\ genotype\ +\ \#\ of\ base\ pairs\ overlapping\ DEL$
$\quad +\ \#\ of\ base\ pairs\ overlapping\ DUP\ +\ sex\ +\ PCs$
$Null\ Model$: $aff \sim sex\ +\ PCs$

Estimating effect sizes for CNVs at 18 loci across 6 diagnostic categories
Effect size estimates from N-weighted meta-analysis are scaled as a Z-score by default. To derive estimates of the odds ratio for each CNV, a mega-analysis was performed on the combined platforms, and odds ratio estimates were added to **Table S9**. For associations with high standard error (SEM>20) in the mega-analysis (due to zero counts in cases or controls), we applied a continuity correction to the effect size estimate similar to the Haldane-Anscombe correction for estimating odds ratios when there is a zero count in a contingency table [99] [100]. To calculate the odds ratio of a CNV that contains a zero count in cases or controls, we added a count of 1 to each cell in the contingency table by randomly sampling 4 subjects from the cohort with replacement (duplicating 2 cases and 2 controls), then the appropriate genotypes were assigned to each (1 case with CNV, 1 case no CNV, 1 control with CNV, 1 control no CNV), and the four subjects were added to the sample.

Assembling HiFi reads from samples carrying the SMYD3 duplication
HiFi long-read whole genome sequencing was performed on 3 samples using the PacBio Revio platform. Minimap2 v2.24 was used for alignment, DeepVariant v1.5 for variant calling, WhatsHap v2.0 for phasing and haplotagging reads, and Flye v2.9.2 for assembly.

Supplemental Material

1138
Supplementary Figures
1139

1140

1141

Figure S1: QC metrics across different platforms in the current PGC CNV study. *For each platform, we show the*
distribution of each QC metric at the sample level including A) The mean Log R Ratio (LRR_MEAN), B) The mean B Allele
Frequency (BAF_MEAN), C) Waviness Factor (WF) D) Log R Ratio standard deviation (LRR_SD), E) B Allele Frequency
standard deviation (BAF_SD), and F) GC waviness factor (GCWF). LRR_SD measures the variability of LRR across a sample
while BAF_SD measures the variability of BAF across a sample. Smaller standard deviation values lead to more accurate CNV
calling. WF measures the total amount of fluctuation in signal intensity in a sample while GCWF measures the amount of
signal intensity fluctuation explained by local GC content.

1149

1150

1151 *Figure S2: Sample groupings for all individuals in the current PGC CNV study.*

1152

1153

Figure S3: Platform/dataset specificity index filter and CNV GWAS for SCZ shows platform-specific spurious
associations. -log₁₀(pvalue) from the SCZ CNV GWAS vs. A) specificity index for platform and B) META-SE standard error are
shown. Deletions and duplications are both included. Previously identified SCZ loci are shown in blue and the rest of the
breakpoints are shown in black. The known loci cluster near lower specificity values and low SE while the spurious
associations that need to be filtered cluster at high SI values and high SE. A threshold of 0.6 SI was chosen to filter out CNVs
coming from a single platform and 0.2 SI for dataset. N-weighted meta-analysis was chosen instead of a threshold for
META-SE. C) Mega-analysis CNV GWAS in SCZ controlling for genotyping platform as a covariate does not properly correct for
genotyping platform. D) CNV GWAS using SE-weighted meta-analysis across platforms does not properly account for
case/control imbalances in different platforms and produces spurious associations with high standard error. E) CNV GWAS
using N-weighted meta-analysis correctly accounts for differences in genotyping platform and case/control imbalances.
Breakpoints filtered by the platform/dataset specificity filter are shown in red. Breakpoints with high standard error are
shown in magenta. Black are all retained breakpoints.

1166
1167 *Figure S4: P-value thresholds for different values of Jaccard Index.* *The red line shows the p-value (6.14x10^{-4}) that gives*
1168 *an FWER of 0.05 based on permutations in the SCZ cohort on chr1.*
1169

1170

Figure S5: Effect sizes of rare CNVs differ by diagnosis, genes, and regions. *A) A CNV burden test for all base pairs was performed for each diagnosis. Rare CNVs contribute to risk in most psychiatric conditions at different magnitudes. B) A CNV burden test was performed for large CNVs with length >1Mb. Results are very similar to all CNVs (Panel A). C) Genes were stratified by their probability of loss of function intolerance (pLI). Tier 1 Genes are defined as pLI > 0.5 and Tier 2 genes have pLI ≤ 0.5. CNVs overlapping Tier 1 genes are enriched in cases with the largest effects in ASD and SCZ. D) CNV burden was tested within the genome-wide significant (GWS) loci identified in this study, clinically-reportable CNVs that were not genome-wide significant in this study (Other loci), and in a combined group (GWS+Other loci)* **Table S6.**

1178

1179

Figure S6: Dose-dependent effects of rare CNVs in different psychiatric traits. *Effect sizes for duplications and deletions show a significant inverse dosage relationship for A) SCZ and B) PTSD. Dosage relationship curves are also shown for C) BD D) MDD E) ADHD and F) ASD.* **Table S9.**

1183

1184

Figure S7: Effect Size across 6 diagnoses for each locus. Effect sizes were estimated by mega-analysis. For summary statistics with high SE, effect sizes were re-estimated with continuity correction. **Table S9**.

References

1. Cross-Disorder Group of the Psychiatric Genomics Consortium *et al.* Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nat. Genet.* **45**, 984–994 (2013).

2. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature* **511**, 421–427 (2014).

3. Malhotra, D. & Sebat, J. CNVs: harbingers of a rare variant revolution in psychiatric genetics. *Cell* **148**, 1223–1241 (2012).

4. Weiner, D. J. *et al.* Polygenic architecture of rare coding variation across 394,783 exomes. *Nature* **614**, 492–499 (2023).

5. Singh, T. *et al.* Rare coding variants in ten genes confer substantial risk for schizophrenia. *Nature* **604**, 509–516 (2022).

6. Sebat, J. *et al.* Strong association of de novo copy number mutations with autism. *Science* **316**, 445–449 (2007).

7. Walsh, T. *et al.* Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science* **320**, 539–543 (2008).

8. International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. *Nature* **455**, 237–241 (2008).

9. Kendall, K. M. *et al.* Association of Rare Copy Number Variants With Risk of Depression. *JAMA Psychiatry* **76**, 818–825 (2019).

10. Maihofer, A. X. *et al.* Rare copy number variation in posttraumatic stress disorder. *Mol. Psychiatry* **27**, 5062–5069 (2022).

11. Pinto, D. *et al.* Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. *Am. J. Hum. Genet.* **94**, 677–694 (2014).

12. Kirov, G. *et al.* De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. *Mol. Psychiatry* **17**, 142–153 (2012).

13. Marshall, C. R. *et al.* Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat. Genet.* **49**, 27–35 (2017).

14. Weiss, L. A. *et al.* Association between microdeletion and microduplication at 16p11.2 and autism. *N. Engl. J. Med.* **358**, 667–675 (2008).

15. Sanders, S. J. *et al.* Insights into Autism Spectrum Disorder Genomic Architecture and Biology from 71 Risk Loci. *Neuron* **87**, 1215–1233 (2015).

16. McCarthy, S. E. *et al.* Microduplications of 16p11.2 are associated with schizophrenia. *Nat. Genet.* **41**, 1223–1227 (2009).

17. Kirov, G. *et al.* Neurexin 1 (NRXN1) deletions in schizophrenia. *Schizophr. Bull.* **35**, 851–854 (2009).

18. Karayiorgou, M., Simon, T. J. & Gogos, J. A. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. *Nat. Rev. Neurosci.* **11**, 402–416 (2010).

19. Stefansson, H. *et al.* Large recurrent microdeletions associated with schizophrenia. *Nature* **455**, 232–236 (2008).

20. Sebat, J., Levy, D. L. & McCarthy, S. E. Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. *Trends Genet.* **25**, 528–535 (2009).

21. Kendall, K. M. *et al.* Cognitive Performance Among Carriers of Pathogenic Copy Number Variants: Analysis of 152,000 UK Biobank Subjects. *Biol. Psychiatry* **82**, 103–110 (2017).

22. Stefansson, H. *et al.* CNVs conferring risk of autism or schizophrenia affect cognition in controls. *Nature* **505**, 361–366 (2014).

23. Qiu, Y. *et al.* Oligogenic Effects of 16p11.2 Copy-Number Variation on Craniofacial Development. *Cell Rep.* **28**, 3320–3328.e4 (2019).

24. Owen, D. *et al.* Effects of pathogenic CNVs on physical traits in participants of the UK Biobank.

bioRxiv (2018) doi:10.1101/355297.

25. Crawford, K. *et al.* Medical consequences of pathogenic CNVs in adults: analysis of the UK
Biobank. *J. Med. Genet.* **56**, 131–138 (2019).

26. Antaki, D. *et al.* A phenotypic spectrum of autism is attributable to the combined effects of rare
variants, polygenic risk and sex. *Nat. Genet.* **54**, 1284–1292 (2022).

27. Davies, R. W. *et al.* Using common genetic variation to examine phenotypic expression and risk
prediction in 22q11.2 deletion syndrome. *Nat. Med.* **26**, 1912–1918 (2020).

28. Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address:
plee0@mgh.harvard.edu & Cross-Disorder Group of the Psychiatric Genomics Consortium.
Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric
disorders. *Cell* **179**, 1469–1482.e11 (2019).

29. Wellcome Trust Case Control Consortium *et al.* Genome-wide association study of CNVs in
16,000 cases of eight common diseases and 3,000 shared controls. *Nature* **464**, 713–720
(2010).

30. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide
association scans. *Bioinformatics* **26**, 2190–2191 (2010).

31. Riggs, E. R. *et al.* Copy number variant discrepancy resolution using the ClinGen dosage
sensitivity map results in updated clinical interpretations in ClinVar. *Hum. Mutat.* **39**,
1650–1659 (2018).

32. ClinGen. Dosage Sensitivity. https://search.clinicalgenome.org/kb/gene-dosage.

33. Guo, R. & Haldeman-Englert, C. R. 1q21.1 recurrent deletion. in *GeneReviews(®)* (University of
Washington, Seattle, Seattle (WA), 1993).

34. Mulle, J. G. *et al.* 3q29 recurrent deletion. in *GeneReviews(®)* (University of Washington, Seattle,
Seattle (WA), 1993).

35. Chung, W. K., Herrera, F. F. & Simon's Searchlight Foundation. Health supervision for children
and adolescents with 16p11.2 deletion syndrome. *Cold Spring Harb. Mol. Case Stud.* **9**, (2023).

36. Óskarsdóttir, S. *et al.* Updated clinical practice recommendations for managing children with
22q11.2 deletion syndrome. *Genet. Med.* **25**, 100338 (2023).

37. Lionel, A. C. *et al.* Disruption of the ASTN2/TRIM32 locus at 9q33.1 is a risk factor in males for
autism spectrum disorders, ADHD and other neurodevelopmental phenotypes. *Hum. Mol.*
Genet. **23**, 2752–2768 (2014).

38. Vrijenhoek, T. *et al.* Recurrent CNVs disrupt three candidate genes in schizophrenia patients.
Am. J. Hum. Genet. **83**, 504–510 (2008).

39. Hogart, A., Wu, D., LaSalle, J. M. & Schanen, N. C. The comorbidity of autism with the genomic
disorders of chromosome 15q11.2-q13. *Neurobiol. Dis.* **38**, 181–191 (2010).

40. Grozeva, D. *et al.* Rare copy number variants: a point of rarity in genetic risk for bipolar
disorder and schizophrenia. *Arch. Gen. Psychiatry* **67**, 318–327 (2010).

41. Charney, A. W. *et al.* Contribution of Rare Copy Number Variants to Bipolar Disorder Risk Is
Limited to Schizoaffective Cases. *Biol. Psychiatry* **86**, 110–119 (2019).

42. Rucker, J. J. H. *et al.* Phenotypic Association Analyses With Copy Number Variation in Recurrent
Depressive Disorder. *Biol. Psychiatry* **79**, 329–336 (2016).

43. Cooper, G. M. *et al.* A copy number variation morbidity map of developmental delay. *Nat. Genet.*
43, 838–846 (2011).

44. Xu, G., Strathearn, L., Liu, B., Yang, B. & Bao, W. Twenty-year trends in diagnosed
attention-deficit/hyperactivity disorder among US children and adolescents, 1997-2016. *JAMA*
Netw. Open **1**, e181471 (2018).

45. Maenner, M. J. *et al.* Prevalence and characteristics of Autism spectrum disorder among
children aged 8 years - Autism and Developmental Disabilities Monitoring network, 11 sites,
United States, 2020. *MMWR Surveill. Summ.* **72**, 1–14 (2023).

46. Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum disorder. *Nat.*

Genet. **51**, 431–444 (2019).

47. Trubetskoy, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in
schizophrenia. *Nature* **604**, 502–508 (2022).

48. Mullins, N. *et al.* Genome-wide association study of more than 40,000 bipolar disorder cases
provides new insights into the underlying biology. *Nat. Genet.* **53**, 817–829 (2021).

49. Howard, D. M. *et al.* Genome-wide meta-analysis of depression identifies 102 independent
variants and highlights the importance of the prefrontal brain regions. *Nat. Neurosci.* **22**,
343–352 (2019).

50. Nievergelt, C. M. *et al.* International meta-analysis of PTSD genome-wide association studies
identifies sex- and ancestry-specific genetic risk loci. *Nat. Commun.* **10**, 4558 (2019).

51. Demontis, D. *et al.* Discovery of the first genome-wide significant risk loci for attention
deficit/hyperactivity disorder. *Nat. Genet.* **51**, 63–75 (2019).

52. Hamad, A. *et al.* Expanding the phenotypic spectrum of Chromosome 16p13.11
microduplication: A multicentric analysis of 206 patients. *Eur. J. Med. Genet.* **66**, 104714 (2023).

53. Woodward, K. J. *et al.* Atypical nested 22q11.2 duplications between LCR22B and LCR22D are
associated with neurodevelopmental phenotypes including autism spectrum disorder with
incomplete penetrance. *Mol. Genet. Genomic Med.* **7**, e00507 (2019).

54. Rees, E. *et al.* Evidence that duplications of 22q11.2 protect against schizophrenia. *Mol.*
Psychiatry **19**, 37–40 (2014).

55. Liu, W., Liu, F., Xu, X. & Bai, Y. Replicated association between the European GWAS locus
rs10503253 at CSMD1 and schizophrenia in Asian population. *Neurosci. Lett.* **647**, 122–128
(2017).

56. Engchuan, W. *et al.* Psychiatric disorders converge on common pathways but diverge in cellular
context, spatial distribution, and directionality of genetic effects. *medRxiv*
2025.07.11.25331381 (2025).

57. Mefford, H. C. & Eichler, E. E. Duplication hotspots, rare genomic disorders, and common
disease. *Curr. Opin. Genet. Dev.* **19**, 196–204 (2009).

58. Lopes, I., Altab, G., Raina, P. & de Magalhães, J. P. Gene Size Matters: An Analysis of Gene Length
in the Human Genome. *Front. Genet.* **12**, 559998 (2021).

59. He, X. *et al.* Integrated model of de novo and inherited genetic variants yields greater power to
identify risk genes. *PLoS Genet.* **9**, e1003671 (2013).

60. Helmrich, A., Ballarino, M. & Tora, L. Collisions between replication and transcription
complexes cause common fragile site instability at the longest human genes. *Mol. Cell* **44**,
966–977 (2011).

61. Sarni, D. *et al.* 3D genome organization contributes to genome instability at fragile sites. *Nat.*
Commun. **11**, 3613 (2020).

62. Mortazavi, M. *et al.* Long-read genome sequencing in clinical psychiatry: RFX3
haploinsufficiency in a hospitalized adolescent with autism, intellectual disability, and
behavioral decompensation. *Am. J. Psychiatry* appiajp20240471 (2025).

63. Modenato, C. *et al.* Effects of eight neuropsychiatric copy number variants on human brain
structure. *Transl. Psychiatry* **11**, 399 (2021).

64. Lin, A. *et al.* Reciprocal Copy Number Variations at 22q11.2 Produce Distinct and Convergent
Neurobehavioral Impairments Relevant for Schizophrenia and Autism Spectrum Disorder. *Biol.*
Psychiatry **88**, 260–272 (2020).

65. Hippolyte, L. *et al.* The Number of Genomic Copies at the 16p11.2 Locus Modulates Language,
Verbal Memory, and Inhibition. *Biol. Psychiatry* **80**, 129–139 (2016).

66. Nguyen, T.-D. *et al.* Genetic heterogeneity and subtypes of major depression. *Mol. Psychiatry* **27**,
1667–1675 (2022).

67. Jacquemont, S. *et al.* Genes To Mental Health (G2MH): A Framework to Map the Combined
Effects of Rare and Common Variants on Dimensions of Cognition and Psychopathology. *Am. J.*

Psychiatry **179**, 189–203 (2022).

68.   Zhang, Y., Li, C. & Yang, Z. Is MYND domain-mediated assembly of SMYD3 complexes involved in calcium dependent signaling? *Front. Mol. Biosci.* **6**, 121 (2019).

69.   Bernard, B. J., Nigam, N., Burkitt, K. & Saloura, V. SMYD3: a regulator of epigenetic and signaling pathways in cancer. *Clin. Epigenetics* **13**, 45 (2021).

70.   Williams, J. B. *et al.* Inhibition of histone methyltransferase Smyd3 rescues NMDAR and cognitive deficits in a tauopathy mouse model. *Nat. Commun.* **14**, 91 (2023).

71.   Fabini, E., Manoni, E., Ferroni, C., Rio, A. D. & Bartolini, M. Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends. *Future Med. Chem.* **11**, 901–921 (2019).

72.   Sanders, S. J. *et al.* Multiple recurrent DE Novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. *Neuron* **70**, 863–885 (2011).

73.   Uhlén, M. *et al.* Proteomics. Tissue-based map of the human proteome. *Science* **347**, 1260419 (2015).

74.   Qiao, H., Tian, Y., Huo, Y. & Man, H.-Y. Role of the DUB enzyme USP7 in dendritic arborization, neuronal migration, and autistic-like behaviors in mice. *iScience* **25**, 104595 (2022).

75.   Chen, H. *et al.* The Hao-Fountain syndrome protein USP7 regulates neuronal connectivity in the brain via a novel p53-independent ubiquitin signaling pathway. *Cell Rep.* **44**, 115231 (2025).

76.   Zhang, X.-W. *et al.* Neuroinflammation inhibition by small-molecule targeting USP7 noncatalytic domain for neurodegenerative disease therapy. *Sci. Adv.* **8**, eabo0789 (2022).

77.   Amici, D. R. *et al.* C16orf72/HAPSTR1 is a molecular rheostat in an integrated network of stress response pathways. *Proc. Natl. Acad. Sci. U. S. A.* **119**, e2111262119 (2022).

78.   Debs, S. R., Rothmond, D. A., Zhu, Y., Weickert, C. S. & Purves-Tyson, T. D. Molecular evidence of altered stress responsivity related to neuroinflammation in the schizophrenia midbrain. *J. Psychiatr. Res.* **177**, 118–128 (2024).

79.   Kushima, I. *et al.* Cross-disorder analysis of genic and regulatory copy number variations in bipolar disorder, schizophrenia, and autism spectrum disorder. *Biol. Psychiatry* **92**, 362–374 (2022).

80.   Wilson, P. M., Fryer, R. H., Fang, Y. & Hatten, M. E. Astn2, a novel member of the astrotactin gene family, regulates the trafficking of ASTN1 during glial-guided neuronal migration. *J. Neurosci.* **30**, 8529–8540 (2010).

81.   Behesti, H. *et al.* ASTN2 modulates synaptic strength by trafficking and degradation of surface proteins. *Proc. Natl. Acad. Sci. U. S. A.* **115**, E9717–E9726 (2018).

82.   The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genome-wide association study identifies five new schizophrenia loci. *Nat. Genet.* **43**, 969–976 (2011).

83.   Coleman, J. R. I. *et al.* The genetics of the mood disorder spectrum: Genome-wide association analyses of more than 185,000 cases and 439,000 controls. *Biol. Psychiatry* **88**, 169–184 (2020).

84.   Stahl, E. A. *et al.* Genome-wide association study identifies 30 loci associated with bipolar disorder. *Nat. Genet.* **51**, 793–803 (2019).

85.   Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. *Nat. Neurosci.* **18**, 199–209 (2015).

86.   Manickam, K. *et al.* Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). *Genet. Med.* **23**, 2029–2037 (2021).

87.   Schaefer, G. B., Mendelsohn, N. J. & Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet. Med.* **15**, 399–407 (2013).

88.   Auwerx, C. *et al.* Rare copy-number variants as modulators of common disease susceptibility.

Genome Med. **16**, 5 (2024).

89. Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank-scale genotype datasets. *Bioinformatics* **33**, 2776–2778 (2017).

90. Chen, C.-Y. *et al.* Improved ancestry inference using weights from external reference panels. *Bioinformatics* **29**, 1399–1406 (2013).

91. Subbiah, M. & Srinivasan, M. R. Classification of 2×2 sparse data sets with zero cells. *Stat. Probab. Lett.* **78**, 3212–3215 (2008).

92. Price, A. L., Zaitlen, N. A., Reich, D. & Patterson, N. New approaches to population stratification in genome-wide association studies. *Nat. Rev. Genet.* **11**, 459–463 (2010).

93. Zhang, Y., Guan, W. & Pan, W. Adjustment for population stratification via principal components in association analysis of rare variants. *Genet. Epidemiol.* **37**, 99–109 (2013).

94. Lupski, J. R. & Stankiewicz, P. Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. *PLoS Genet.* **1**, e49 (2005).

95. Adam, M. P. *et al. GeneReviews(®)*. (University of Washington, Seattle, Seattle (WA), 1993).

96. Clinical Genome Resource. Welcome to ClinGen. https://clinicalgenome.org/.

97. Home - OMIM. https://www.omim.org/.

98. Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. *J. Stat. Softw.* **36**, 1–48 (2010).

99. Haldane, J. B. S. The mean and variance of the moments of chi-squared when used as a test of homogeneity, when expectations are small. *Biometrika* **29**, 133–134 (1940).

100. Anscombe, F. J. On estimating binomial response relations. *Biometrika* **43**, 461–464 (1956).